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Elevated Potassium Levels in Patients With Congestive Heart Failure:
Occurrence, Risk Factors, and Clinical Outcomes
A Danish Population-Based Cohort Study
Reimar Wernich Thomsen, MD, PhD; Sia Kromann Nicolaisen, MSc; Pal Hasvold, MSc, PhD; Ricardo Garcia-Sanchez, MD; Lars Pedersen,
MSc, PhD; Kasper Adelborg, MD, PhD; Martin Egfjord, MD, DMSc; Kenneth Egstrup, MD, DMSc; Henrik Toft Sørensen, MD, PhD, DMSc
Background-—Data on the true burden of hyperkalemia in patients with heart failure (HF) in a real-world setting are limited.
Methods and Results-—Incidence rates of hyperkalemia (ﬁrst blood test with a potassium level >5.0 mmol/L) in primary or
hospital care were assessed in a population-based cohort of patients with incident HF diagnoses in northern Denmark from 2000
to 2012. Risk factors and clinical outcomes were compared in patients with HF with versus without hyperkalemia. Of 31 649
patients with HF, 39% experienced hyperkalemia (mean follow-up, 2.2 years). Risks of experiencing a second, third, or fourth event
were 43%, 54%, and 60%, respectively. Among patients with HF with stage 3A, 3B, 4, or 5 kidney dysfunction, 26%, 35%, 44%, and
48% experienced hyperkalemia within the ﬁrst year. Important hyperkalemia risk factors included chronic kidney disease
(prevalence ratio, 1.46; 95% conﬁdence interval [CI], 1.431.49), diabetes mellitus (prevalence ratio, 1.38; 95% CI, 1.321.45),
and spironolactone use (prevalence ratio, 1.48; 95% CI, 1.421.54). In patients with HF who developed hyperkalemia, 53% had any
acute-care hospitalization 6 months before the hyperkalemia event, increasing to 74% 6 months after hyperkalemia (before-after
risk ratio, 1.41; 95% CI, 1.381.44). Compared with matched patients with HF without hyperkalemia, adjusted 6-month hazard
ratios in patients with hyperkalemia were 2.75-fold (95% CI, 2.65–2.85) higher for acute-care hospitalization and 3.39-fold (95% CI,
3.19–3.61) higher for death.
Conclusions-—Almost 4 in 10 patients with HF develop hyperkalemia, and many patients have recurrent hyperkalemia episodes.
Hyperkalemia risk is strongly associated with degree of reduced kidney function and use of spironolactone. Hyperkalemia is
associated with severe clinical outcomes and death in HF. ( J Am Heart Assoc. 2018;7:e008912. DOI: 10.1161/JAHA.118.
008912.)
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H eart failure (HF) affects >37 million adults worldwideand is a leading cause of hospitalizations and death.1,2
Despite improvements in HF therapy and prognosis,3
hospitalizations with HF remain frequent, and comorbidities,
including diabetes mellitus and renal disease, have become
more common.2–5
Hyperkalemia, usually deﬁned as blood potassium level
>5.0 mmol/L, is a concern in patients with HF in everyday
clinical practice and can be a life-threatening condition.6,7
Hyperkalemia with high potassium levels (eg, >6.0 mmol/L)
may lead to cardiac arrhythmias and death,8 but even
potassium levels of >5.0 mmol/L have been associated with
increased mortality in patients with acute-care hospital
admission6 and in patients with HF.9,10
Knowledge is scarce on the occurrence of hyperkalemia
and associated outcomes in patients with HF in the real-world
setting.11,12 Patients with kidney disease have an increased
risk of hyperkalemia,7 and a dynamic association between
heart and kidney dysfunction has been described in the
cardiorenal syndrome,13 with evidence of chronic kidney
disease in more than half of patients with HF.14 Moreover,
several drugs commonly used for treating HF may lead to
hyperkalemia15 by interfering with renal potassium excretion,
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including angiotensin-converting enzyme inhibitors (ACEis),
angiotensin receptor blockers (ARBs), and potassium-sparing
diuretics, such as spironolactone and eplerenone.11,16
To understand the potential impact of new drug therapies
for hyperkalemia,8,17 it is important to assess the true burden
of hyperkalemia among people with HF and to assess
associated patient characteristics, current treatment prac-
tices, and clinical outcomes in real-world settings. We,
therefore, undertook a large population-based cohort study
in Denmark to examine occurrence, risk factors, and
outcomes of hyperkalemia in patients with HF.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results. According to Danish legislation, research-
ers may apply for the data at the Danish Health Data
Authority.
Setting
This cohort study was conducted in northern Denmark, by
using routine care laboratory test results from both primary
and hospital care for the entire region’s population
(1 851 496 residents [33% of Denmark’s population] by the
end of 2012).18 The laboratory data were linked using the Civil
Personal Registration number with data from the Danish
National Patient Registry, which contains dates of admission
and discharge (including emergency department and outpa-
tient clinic visits) and procedures.19 Furthermore, data on
drugs were retrieved from the Aarhus University Prescription
Database, which holds records of type of drug, date of
dispensing, and quantity on all prescribed drugs dispensed
from Danish pharmacies in northern Denmark.20
Patients With HF and Covariates
From the source population of all individuals living in northern
Denmark, we identiﬁed a cohort of individuals with a ﬁrst-time
inpatient hospital admission with a primary or secondary
discharge diagnosis of HF between 2000 and 2012. The HF
diagnosis has a positive predictive value of 80% in the
Danish National Patient Registry.21 On the basis of the lowest
estimated glomerular ﬁltration rate (eGFR) measured up to
and including the date of ﬁrst HF admission (or presence of
dialysis), patients were classiﬁed into kidney disease stage 1
and 2, eGFR ≥60 mL/min per 1.73 m2; stage 3A, eGFR of 45
to 59 mL/min per 1.73 m2; stage 3B, eGFR of 30 to 44 mL/
min per 1.73 m2; stage 4, eGFR of 15 to 29 mL/min per
1.73 m2; stage 5, eGFR of <15 mL/min per 1.73 m2; and
dialysis.22 Baseline characteristics at time of the ﬁrst HF
admission were based on dispensed drugs from pharmacies
within the past 12 months and on diagnoses and procedures
recorded in the National Patient Registry any time up to and
including the date of HF discharge. Patients were followed up
for hyperkalemia events from the time of the ﬁrst HF hospital
admission until migration, death, or end of follow-up.
All codes and variable algorithms used in the study are
provided in Table S1.
Statistical Analysis
Incidence of hyperkalemia
An incident episode of hyperkalemia was deﬁned as an
elevated blood potassium level >5.0 mmol/L not preceded by
a prior episode of elevated potassium within the previous
month. Incidence of hyperkalemia events with cut points
potassium >5.5 mmol/L and potassium >6.0 mmol/L was
examined separately. Incidence rates of a ﬁrst hyperkalemia
event per 1000 person-years were calculated. Cumulative
incidence function curves were constructed, and risks
(cumulative incidence proportions) of developing hyper-
kalemia within 1 and 3 years were estimated. The risk of
developing a second, third, and fourth hyperkalemia event
was also described.
Clinical Perspective
What Is New?
• To understand the potential impact of new drug therapies
for hyperkalemia, it is important to assess the true burden
of hyperkalemia among people with heart failure (HF).
• In a population-based cohort study including 31 649
patients with ﬁrst hospital-diagnosed HF, almost 4 in 10
patients developed hyperkalemia (potassium >5.0 mmol/L)
over 2.2 years.
• The risk of developing hyperkalemia was strongly associated
with degree of reduced kidney function and spironolactone
use, and recurrent hyperkalemia was frequent.
• Compared with matched patients with HF without hyper-
kalemia, events of hyperkalemia were associated with
severe clinical outcomes, including arrhythmias, intensive
care admission, and death.
What Are the Clinical Implications?
• Among patients with HF in everyday clinical care, attention
to the substantial risk of hyperkalemia is prudent.
• Efforts to prevent and normalize hyperkalemia should be
directed to patients with HF, chronic kidney disease, and
diabetes mellitus, and to those who use spironolactone.
• Our data support the need for regular potassium measure-
ment to identify patients with HF at risk of serious clinical
outcomes and death.
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Risk factors at the time of hyperkalemia
To examine risk factors before the hyperkalemia/index date,
one comparison patient without hyperkalemia was matched to
each corresponding patient with hyperkalemia on the index
date, according to sex, age, calendar time, and time since ﬁrst
HF admission. Prevalence ratios (PRs) for the association of
speciﬁed risk factors were calculated.
Outcomes associated with hyperkalemia
In a before-after analysis among patients with HF who all had
experienced hyperkalemia, the cumulative incidence propor-
tion ratios (risk ratios [RRs]) of experiencing each individual
clinical outcome during the 6 months after, versus 6 months
before, the hyperkalemia event date were calculated, account-
ing for competing risk of death within 6 months after the
hyperkalemia date.
Second, a matched cohort design with Cox regression was
used to estimate the hazard ratio (HR) of clinical outcomes
6 months after the hyperkalemia/index date in patients with
hyperkalemia versus age, sex, and HF duration matched
comparisons without hyperkalemia. Factors potentially asso-
ciated with both hyperkalemia risk and outcomes were
adjusted for, including intensity of HF treatment regimen
and number of acute HF hospitalizations 6 months before the
hyperkalemia/index date as marker of HF severity, eGFR
category, Charlson Comorbidity Index score, presence of
speciﬁc hyperkalemia risk factors (diabetes mellitus/chronic
kidney disease/hypertension), and use of ACEis/ARBs,
spironolactone, or potassium supplements.
Additional and Sensitivity Analyses
Although potassium tests were generally frequent in the HF
cohort (mean, 23 tests; median, 15 tests; interquartile range,
5–31 tests per patient during the observation period), bias by
indication for blood testing may be a concern (ie, sicker
patients possibly receiving more frequent blood testing with
higher likelihood of hyperkalemia being detected). Therefore,
the analyses were repeated using a randomly selected set of 5
potassium tests per patient among patients with HF with at
least 5 tests the year after HF. Second, to study hyperkalemia
impact in a subcohort more likely to have chronic HF, and thus
be more closely followed up, patients who were alive at
6 months after HF discharge had an echocardiography
performed and were treated with both ARBs or ACEis and b
blocker up to this date were separately examined. Third, as an
alternative method to account for remaining unmeasured
confounding when comparing outcomes in patients with and
without hyperkalemia with HF, the ratio of the 2 matched HRs
observed after versus before the hyperkalemia/index date (ie,
the prior event rate ratio adjusted rate ratio) was estimated.23
This method is based on the assumption that differences in
outcomes between hyperkalemia-exposed and matched hyper-
kalemia-unexposed patients present already before experienc-
ing hyperkalemia reﬂect the combined effect of remaining
unmeasured confounders, independent of any effect of
hyperkalemia. Fourth, to exclude reverse causality (ie, acute-
care hospitalization outcomes, such as intensive care unit
admission, leading to secondary hyperkalemia, versus being a
consequence of hyperkalemia), outcomes were also examined
separately for hyperkalemia detected on the ﬁrst admission
date of any hospitalization. Fifth, analyses were stratiﬁed by
initial HF diagnosis being primary (ﬁrst-listed) versus sec-
ondary diagnosis. Sixth, we evaluated outcomes separately for
elevated potassium detected on dates on which patients were
hospitalized versus out of hospital, and we repeated the
outcome analyses separately in patients with <10 potassium
tests versus patients with ≥10 tests before the hyperkalemia
event. Finally, the inﬂuence of potential unmeasured con-
founding was quantiﬁed by means of a rule-out approach.24 We
estimated how strongly an unmeasured binary confounder
would need to be associated with hyperkalemia and outcomes
to fully explain our ﬁndings, and we illustrated this association
graphically.
The study was approved by the Danish Data Protection
Agency. The study was purely registry based and did not involve
any contact with patients or interventions; therefore, according
to Danish legislation, no informed consent was required.
Results
Baseline Characteristics
Overall, the analysis comprised 31 649 individuals with a ﬁrst
incident hospital record of HF in northern Denmark from 2000
to 2012. Median age was high, at 78 (interquartile range, 69–
85) years, and 47% were women (Table 1). Diagnosed
cardiomyopathy at time of ﬁrst HF diagnosis was relatively
rare (4%), whereas 14% had known valvular heart disease, 21%
had prior MI, 40% had any ischemic heart disease, 35% had
atrial ﬁbrillation, and 62% had hypertension. In total, two
thirds (68%) of the patients had a history of hospital-
diagnosed comorbidities included in the Charlson Comorbidity
Index on admission; 19% had diabetes mellitus, 41% had
chronic kidney disease, and 18% had chronic pulmonary
disease. At baseline before ﬁrst admission, 24% of the
patients were treated with ACEis, 11% were treated with
ARBs, 31% were treated with bblockers, 11% were treated
with spironolactone, and 30% were treated with potassium
supplements. Of the patients, 57% had been examined with
echocardiography. Three months after initial HF diagnoses,
proportions with echocardiography and receiving drug treat-
ment had increased considerably in our cohort, as expected
(for subpopulation with chronic HF, see later).
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Incidence of Hyperkalemia
During 69 318 person-years of follow-up (mean, 2.2 years),
39% (n=12 340) of the patients experienced a ﬁrst hyper-
kalemia event with potassium of >5.0 mmol/L, resulting in an
incidence rate of 178 per 1000 person-years (Table 1),
increasing with age and comorbidity (Table S2). The cumu-
lative risk of hyperkalemia was 25% during the ﬁrst year and
32% within 3 years after HF diagnosis. Among patients with
stage 3A, 3B, 4, or 5 kidney disease, or dialysis, 26%, 35%,
44%, 48%, and 48% experienced hyperkalemia within the ﬁrst
year. Median time to ﬁrst hyperkalemia event in those who
experienced an event was 0.34 years; 7787 events (63%)
were hospital diagnosed.
The panels of Figure 1 each display cumulative incidence
curves of ﬁrst event of potassium >5.0 mmol/L, potassium
>5.5 mmol/L, or potassium >6.0 mmol/L by decreasing
kidney function. Almost half (43%) of all patients with a ﬁrst
hyperkalemia event had a second event, whereas risks of
experiencing a third event or fourth event were 54% and 60%,
respectively, with successively shorter time between the
episodes (Figure 2).
Risk Factors of Hyperkalemia
Patients who developed hyperkalemia had similar underlying
HF causes as those who did not develop hyperkalemia, but
most comorbidities were more common in those with
hyperkalemia (Table 2). Use of spironolactone was also
increased, whereas use of other hyperkalemia-associated
medications at the time of hyperkalemia was not higher. There
was an association between hyperkalemia and decreasing
eGFR values (eGFR 30–44 mL/min per 1.73 m2: PR, 1.38; 95%
conﬁdence interval [CI], 1.33–1.45; eGFR 15–29 mL/min per
1.73 m2: PR, 2.05; 95% CI, 1.94–2.17; eGFR <15 mL/min per
1.73 m2: PR, 2.83; 95% CI, 2.49–3.21), and with presence of
chronic kidney disease overall (PR, 1.46; 95% CI, 1.431.49),
diabetes mellitus (PR, 1.38; 95% CI, 1.321.45), peripheral
vascular disease (PR, 1.34; 95% CI, 1.301.43), and use of
spironolactone (PR, 1.48; 95% CI, 1.421.54). The relative
importance of risk factors increased, by higher potassium level
(Table S3).
Clinical Outcomes of Hyperkalemia
In patients with hyperkalemia, the incidence proportion with
any acute-care hospitalization was 53% within 6 months
before the hyperkalemia event, increasing to 74% 6 months
after the hyperkalemia event, corresponding to a competing
risk of death adjusted before-after RR of 1.41 (95% CI,
1.381.44) (Figure 3). The risk for any cardiac hospital
diagnosis increased from 44% to 61% (before-after RR, 1.46;
95% CI, 1.431.50), for HF hospitalization from 33% to 43%
(RR, 1.42; 95% CI, 1.37–1.46), for ventricular arrhythmias
from 2.4% to 3.6% (RR, 1.90; 95% CI, 1.652.18), for
Figure 1. Cumulative incidence curves for ﬁrst occurrence of potassium >5.0 mmol/L, potassium >5.5 mmol/L, or potassium >6.0 mmol/L
in patients with ﬁrst hospital diagnosed heart failure, according to estimated glomerular ﬁltration rate (eGFR) category.
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intensive care unit admissions from 3.3% to 14.9% (RR, 5.29;
95% CI, 4.775.86), for ventilator therapy from 1.3% to 8.0%
(RR, 7.17; 95% CI, 6.10–8.43), and for cardiac arrest from
0.2% to 1.3% (RR, 9.89; 95% CI, 6.17–15.84). Six-month
mortality after hyperkalemia was 36%. Among patients who
survived after hyperkalemia, discontinuation of hyperkalemia-
associated drugs was rarely seen (eg, adjusted RRs were
1.02, 1.11, and 1.10 for ARBs, ACEis, and spironolactone, yet
Figure 2. Proportions and median follow-up time for patients with heart failure (HF) experiencing recurrent hyperkalemia (HK) events.
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Table 2. Prevalence of Risk Factors at Time of Hyperkalemia/Index Date Among Patients With HF With Hyperkalemia and
Matched Comparisons Without Hyperkalemia
Variable
Patients With HF With First
Hyperkalemia >5.0 mmol/L
Matched HF Comparisons
Without Hyperkalemia* Matched PR (95% CI)
No. of patients 12 340 (100) 12 151 (100) . . .
Female sex 5670 (45.9) 5581 (45.9) . . .
Age, median (quartiles), y 78.6 (70.2–85.1) 78.7 (70.6–85.0) . . .
Potassium tests 6 mo before
hyperkalemia/index date, median (quartiles)
5.0 (2.0–11.0) 2.0 (0.0–6.0) . . .
Acute HF hospitalizations 6 mo before
hyperkalemia/index date, median (quartiles)
0.0 (0.0–1.0) 0.0 (0.0–1.0) . . .
Conditions underlying HF†
Cardiomyopathy 925 (7.5) 806 (6.6) 1.13 (1.03–1.24)
Valvular heart disease 2182 (17.7) 1754 (14.4) 1.22 (1.16–1.30)
Myocardial infarction 3551 (28.8) 3236 (26.6) 1.08 (1.0–1.13)
Any ischemic heart disease 5796 (47.0) 5268 (43.4) 1.08 (1.05–1.11)
Atrial fibrillation 4843 (39.2) 4679 (38.5) 1.02 (0.99–1.05)
Lowest eGFR measured before hyperkalemia/index date
No values <60 mL/min per 1.73 m2 1636 (13.3) 2530 (20.8) 0.64 (0.60–0.67)
eGFR 45–59 mL/min per 1.73 m2 2502 (20.3) 3062 (25.2) 0.80 (0.77–0.84)
eGFR 30–44 mL/min per 1.73 m2 3702 (30.0) 2633 (21.7) 1.38 (1.33–1.45)
eGFR 15–29 mL/min per 1.73 m2 3119 (25.3) 1498 (12.3) 2.05 (1.94–2.17)
eGFR <15 mL/min per 1.73 m2 896 (7.3) 312 (2.6) 2.83 (2.49–3.21)
Dialysis 235 (1.9) 73 (0.6) 3.17 (2.44–4.12)
No eGFR measurement recorded 250 (2.0) 2043 (16.8) 0.12 (0.11–0.14)
Selected predefined risk factors for hyperkalemia
Diabetes mellitus 3425 (27.8) 2440 (20.1) 1.38 (1.32–1.45)
Chronic kidney disease‡ 8139 (66.0) 5489 (45.2) 1.46 (1.43–1.49)
Hypertension 10 180 (82.5) 9454 (77.8) 1.06 (1.05–1.07)
Other comorbidities
Peripheral vascular disease 2050 (16.6) 1503 (12.4) 1.34 (1.3–1.43)
Cerebrovascular disease 2483 (20.1) 2333 (19.2) 1.05 (1.0–1.10)
Chronic pulmonary disease 3327 (27.0) 2797 (23.0) 1.17 (1.1–1.22)
Peptic ulcer disease 1483 (12.0) 1214 (10.0) 1.20 (1.1–1.29)
Any malignant disease 2143 (17.4) 1881 (15.5) 1.12 (1.06–1.19)
Alcoholism-related disorders 1193 (9.7) 937 (7.7) 1.25 (1.16–1.36)
Medical obesity 1110 (9.0) 881 (7.3) 1.24 (1.14–1.35)
Use of hyperkalemia-associated medications
ACEis overall 5580 (45.2) 5113 (42.1) 1.07 (1.04–1.11)
Ramipril 2700 (21.9) 2337 (19.2) 1.14 (1.08–1.20)
Enalapril 1284 (10.4) 1059 (8.7) 1.19 (1.10–1.29)
Other ACEis 1624 (13.2) 1717 (14.1) 0.93 (0.87–0.99)
ACEi/diuretic combination 306 (2.5) 299 (2.5) 1.01 (0.86–1.18)
ARBs overall 1779 (14.4) 1663 (13.7) 1.05 (0.99–1.12)
Losartan 775 (6.3) 794 (6.5) 0.96 (0.87–1.06)
Continued
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0.90 for potassium supplements) (Figure 3). Reductions in
average deﬁned daily doses were rarely observed in those
who continued drugs (eg, for ACEis, 2.0 and 1.9 deﬁned daily
doses before and after; for ARBs, 1.4 deﬁned daily doses both
before and after; data not shown).
When compared with matched patients without hyper-
kalemia, and adjusting for the prior event increased HRs,
6-month HRs for clinical outcomes after the index date were
higher in patients with hyperkalemia: 2.3-fold higher for any
acute-care hospitalization, 2.3-fold higher for ventricular
arrhythmias, 4.4-fold higher for intensive care unit admission,
and 7.3-fold higher for cardiac arrest. The 6-month adjusted
HR of death was 3.39 (95% CI, 3.19–3.61) (Table 3). Outcome
RRs were generally higher for more pronounced potassium
elevations (Table S4).
When restricted to the subcohort of patients with chronic
HF, incidences of hyperkalemia increased less steeply during
early follow-up, but total hyperkalemia incidence rates were
close to those in all patients with HF, with similar risk factors,
whereas outcome RRs after hyperkalemia were less high
(Tables S5 through S7). When repeating analyses using 5
random potassium tests per person (Tables S8 through S10),
incidences of hyperkalemia were modestly reduced versus the
main analysis (1-year cumulative incidence decreased from
25.2% to 20.9%), risk factor estimates were similar, and
outcome associations with hyperkalemia were weaker (eg,
adjusted HR for acute-care hospitalization, 1.99 [main anal-
ysis, 2.75]; adjusted HR for intensive care unit, 3.18 [main
analysis, 5.12)]. When repeating analyses for those with initial
HF as primary diagnosis, all results remained robust and were
similar to the main analysis (Tables S11 through S13). The
associations between hyperkalemia and clinical outcomes
were generally stronger when potassium was measured on in-
hospital days than out-of-hospital days (Tables S14 and S15)
and in patients with ≥10 potassium tests than in patients with
<10 potassium tests (Tables S16 and S17). Finally, when
quantifying the inﬂuence of potential unmeasured confound-
ing (Figure S1), we found that to explain an adjusted HR of
2.0 for acute-care hospitalizations associated with hyper-
kalemia, a confounder that was 4 times more frequent among
patients with hyperkalemia, compared with patients without
hyperkalemia, would need to increase the hazard of acute-
care hospitalization by a factor of ≥10 to explain our ﬁndings
fully (if no increased hazard actually existed).
Discussion
This population-based cohort study provides a longitudinal
overview of hyperkalemia occurrence, risk factors, and
prognosis in patients with incident HF in Denmark over
13 years. Approximately 1 in 4 patients with incident hospital-
diagnosed HF developed hyperkalemia within the ﬁrst year,
whereas risk of hyperkalemia was even higher in patients with
both HF and kidney disease. Recurrent hyperkalemia episodes
were common. Individuals treated with spironolactone and
those with diabetes mellitus and renal failure were at
particularly increased risk. Hyperkalemia was strongly asso-
ciated with adverse clinical outcomes in patients with HF,
including 1.4-fold higher risk of acute-care and cardiac
hospitalizations compared with the time period before
hyperkalemia in the same patients, and 2.2-fold higher
rates of these outcomes and 3.2-fold higher mortality
Table 2. Continued
Variable
Patients With HF With First
Hyperkalemia >5.0 mmol/L
Matched HF Comparisons
Without Hyperkalemia* Matched PR (95% CI)
Candesartan 414 (3.4) 297 (2.4) 1.37 (1.19–1.59)
Other ARBs 308 (2.5) 252 (2.1) 1.20 (1.02–1.42)
ARB/diuretic combination 425 (3.4) 468 (3.9) 0.89 (0.79–1.02)
Spironolactone 4125 (33.4) 2753 (22.7) 1.48 (1.42–1.54)
Potassium supplements 6229 (50.5) 6100 (50.2) 1.01 (0.98–1.03)
Loop diuretics 8130 (65.9) 7683 (63.2) 1.04 (1.02–1.06)
NSAIDs 2727 (22.1) 2705 (22.3) 0.99 (0.95–1.04)
Trimethoprim 428 (3.5) 371 (3.1) 1.14 (0.99–1.30)
Macrolides 1598 (12.9) 1413 (11.6) 1.11 (1.04–1.19)
Data are given as number (percentage) unless otherwise indicated. Percentages are based on the ﬁrst row. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor II blocker; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; NSAIDS, nonsteroidal anti-inﬂammatory drugs; PR, prevalence ratio.
*HF comparison patients without hyperkalemia matched on age, sex, and duration of HF on the hyperkalemia/index date.
†As present at the time of HF diagnosis.
‡Manifest chronic kidney disease was deﬁned on the date of the second of 2 measurements >90 days apart of a creatinine value corresponding to an eGFR <60 mL/min per 1.73 m2 or
on the ﬁrst date of a hospital diagnosis of chronic kidney disease (see Table S1 for codes).
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Figure 3. Clinical outcomes before and after hyperkalemia (HK). Dark gray bars show outcomes 6 months
before and after the HK date in patients with heart failure with HK. Corresponding after vs before risk ratios are
shown, adjusted for competing risk of death after HK. Light gray bars show outcomes in age-, sex-, and heart
failure duration–matched patients with heart failure without HK as a point of comparison. ACEi indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, conﬁdence interval; ICU,
intensive care unit.
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compared with matched patients with HF without
hyperkalemia.
Our ﬁndings are consistent with previous studies, but they
suggest that the real-world burden of hyperkalemia is even
greater in patients with cardiorenal syndrome than
anticipated.25 In the PARADIGM-HF (Prospective Comparison
of ARNI With ACEI to Determine Impact on Global Mortality
and Morbidity in Heart Failure) study, 15% in both treatment
groups developed hyperkalemia within a median follow-up of
27 months,26 whereas the risks of hyperkalemia in patients
with HF were generally lower in a UK observational study11
and in several other randomized controlled trials.27 The risk of
hyperkalemia was substantially higher in our study, which
likely mirrors a different universal healthcare system with
inclusion of all hospital contacts with HF, including also
elderly, comorbid, and frail patients. Our ﬁndings indicate that
the true real-world burden of hyperkalemia is even greater
than anticipated and highlight that patients with the cardiore-
nal syndrome are at particular high risk of hyperkalemia. In
our current analysis, risk factors for hyperkalemia included
chronic kidney disease, diabetes mellitus, and use of
spironolactone, as corroborated by others’ ﬁndings.11,12,28–30
Our study adds to the literature on the prognostic impact
of hyperkalemia among patients with HF. In a Danish cohort
study of 2596 patients with myocardial infarction receiving
loop diuretics (as a proxy for HF), all levels of elevated
potassium, including slightly increased levels, predicted death
from any cause (4.6–5.0 mmol/L: adjusted HR, 1.6; 5.1–
5.5 mmol/L: adjusted HR, 2; >5.5 mmol/L, adjusted HR,
5.6).9 Similarly, among 7788 patients with chronic HF in the
Figure 3. Continued.
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Digitalis Investigation Group trial, mild hyperkalemia was
associated with 15% increased mortality.10 However, mild
hyperkalemia was not associated with cardiovascular or HF
mortality or all-cause or cardiovascular hospitalization. Among
3900 patients admitted with acute HF in the Patients
Hospitalized with acute heart failure and Volume Overload
to Assess Treatment Effect on Congestion and Renal Function
(PROTECT) and Coordinating Study Evaluating Outcomes of
Advising and Counseling Failure (COACH) trials, admission
potassium levels of >5.0 mEq/L versus normal potassium
level were associated with a 2.36-fold increased risk of death
after 6 months.30 However, the association weakened con-
siderably and became nonsigniﬁcant after multivariate adjust-
ment for kidney dysfunction and other predictors. Comparison
with our study is difﬁcult because we examined hyperkalemia
as a risk factor for being acutely hospitalized with different
conditions, and for mortality as a separate outcome, rather
than studying hyperkalemia as a prognostic factor among
patients already acutely hospitalized with HF. Our ﬁndings
extend current knowledge, suggesting that elevated potas-
sium levels >5.0 mmol/L may be associated with higher risk
of cardiovascular hospitalizations and arrhythmias in patients
with HF.
Although most current guidelines for HF recommend
clinicians to consider stopping or reducing dose of ACEi/
ARB or potassium-sparing diuretics if potassium increases
>5.5 mmol/L,15 the proportion of users and the dosing of
these drugs remained broadly unchanged after the initial
hyperkalemia event. Potential explanations may include that
some patients had potassium levels <5.5 mmol/L or that
some patients had transient elevated potassium levels not
requiring cessation of treatment.
Any conclusions oncausalmechanisms in our study should be
made with caution. Hyperkalemia measured in association with
acute-carehospitalizationmaybeaconsequenceof thecondition
leading to hospital contact (eg, infection, dehydration, or
deteriorating kidney function), rather than causing the hospital-
ization. The exact order of events in the pathophysiological
pathway leading to a acute-care hospitalization is difﬁcult to
disentangle. It is impossible to determine in our registry-based
study, in which patients with hyperkalemia did not have any
bearing on the acute-care hospitalization and its course. How-
ever, the ﬁndings that outcome RRs were higher for more severe
versus mild hyperkalemia events and that speciﬁc diagnoses,
such as cardiac arrhythmia or cardiac arrest, were associated
with high levels of potassium argue for a causal association.
Table 3. HRs for Clinical Outcomes 6 Months After Hyperkalemia Versus Fully Matched Comparisons Without Hyperkalemia
Outcome
Patients With HF With First
Hyperkalemia >5.0 mmol/L
Matched HF Comparisons
Without Hyperkalemia*
Fully Adjusted
HR (95% CI)†
Prior Event Rate Ratio
Adjusted HR (95% CI)‡n (Rate per 1000 Person-Years) n (Rate per 1000 Person-Years)
Any hospital outpatient contact 7760 (3204.49) 6444 (1717.40) 1.64 (1.58–1.70) 1.39 (1.34–1.46)
Any acute-care hospitalization 9100 (4499.29) 5101 (1261.17) 2.75 (2.65–2.85) 2.26 (2.17–2.35)
Any non–acute-care hospitalization 2786 (778.41) 1913 (381.40) 1.93 (1.81–2.06) 1.65 (1.53–1.78)
Any cardiac diagnosis 7492 (3017.17) 4198 (980.49) 2.47 (2.37–2.58) 2.19 (2.09–2.29)
Ventricular arrhythmia 450 (104.85) 230 (41.67) 2.27 (1.91–2.69) 2.33 (1.88–2.88)
Cardiac arrest 156 (35.42) 41 (7.35) 5.34 (3.70–7.73) 7.30 (3.55–16.01)
Dialysis procedure 223 (51.06) 61 (10.95) 1.75 (1.30–2.35) 1.18 (0.85–1.60)
Ventilator treatment 990 (233.90) 185 (33.38) 6.80 (5.77–8.02) 4.46 (3.29–5.86)
ICU admission 1837 (460.02) 459 (83.93) 5.12 (4.60–5.71) 4.42 (3.80–5.29)
HF readmission 5309 (1718.65) 3147 (692.21) 2.15 (2.05–2.26) 1.96 (1.88–2.05)
ACEi prescription 4430 (1572.70) 4863 (1311.79) 1.05 (1.01–1.10) 0.99 (0.95–1.02)
ARB prescription 1223 (305.03) 1406 (276.36) 1.00 (0.92–1.09) 1.03 (0.97–1.09)
Spironolactone prescription 3182 (943.22) 2876 (625.89) 1.07 (1.02–1.13) 0.84 (0.81–0.88)
Potassium supplement prescription 4109 (1326.70) 5919 (1713.53) 0.81 (0.78–0.84) 0.75 (0.72–0.78)
Death 4457 (1006.59) 1542 (276.03) 3.39 (3.19–3.61) –
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, conﬁdence interval; HF, heart failure; HR, hazard ratio; ICU, intensive care unit.
*HF comparisons without hyperkalemia individually matched to patients with HF with hyperkalemia on age, sex, and HF duration (see Statistical Analysis section).
†Adjusted for age, sex, and HF duration by matched design and, by Cox regression analyses, for HF treatment regimen, number of acute HF hospitalizations 6 months before the
hyperkalemia/index date, estimated glomerular ﬁltration rate category, Charlson Comorbidity Index score, presence of diabetes mellitus/chronic kidney disease/hypertension, use of
ACEis/ARBs, spironolactone, or potassium supplements.
‡The prior event rate ratio adjusted HR is the ratio of the 2 age, sex, and HF duration matched rate ratios observed 6 months after vs 6 months before the hyperkalemia/index date. (see
Additional and Sensitivity Analyses section).
DOI: 10.1161/JAHA.118.008912 Journal of the American Heart Association 13
Hyperkalemia in Heart Failure Thomsen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on May 7, 2019
Interestingly, the results of our analysis were consistent in
a subset of patients with chronic HF receiving ACEi/ARB
blockade and b blockers in whom 40% had chronic kidney
disease (eGFR <45 mL/min per 1.73 m2). This indicates that
careful surveillance of potassium levels is important in
patients with chronic HF, and future studies should address
the role for novel prevention and treatment strategies.
Our real-world observational study of the burden of
hyperkalemia in patients with HF has both strengths and
weaknesses. The Danish public healthcare system permitted a
population-based design with inclusion of all patients with
incident HF and subsequent incident hyperkalemia in a well-
deﬁned geographical region. This largely eliminated some of
the selection problems encountered in clinic-based or health
insurance–based observational studies.
The validity of our ﬁndings depends on the completeness
and quality of registry data. We relied on potassium and other
tests ordered in everyday clinical practice (ie, by medical
indication for measurement). Sicker patients may have had a
higher likelihood of any hyperkalemia being detected because
of higher frequency of testing, leading to potential overesti-
mation of hyperkalemia incidence and possibly also its clinical
consequences. However, our patients all had in-hospital–
diagnosed HF and are all likely to receive regular blood tests
in a universally covering healthcare system, as demonstrated
by the high average number of potassium tests observed.
Moreover, we were able to control for several HF severity
markers and other prognostic predictors. Our registry data did
not allow for further adjustment for potential differences in
left ventricular ejection fraction or New York Heart Associa-
tion class.
Hyperkalemia incidence and adverse outcomes decreased
modestly but remained high when only examining several
random potassium tests per person. Moreover, associations
between hyperkalemia and clinical outcomes were generally
stronger, not weaker, when focusing on people with many
potassium tests, arguing against potassium elevations being
casual ﬁndings. The less severe outcome observed with
hyperkalemia measured on out-of-hospital versus in-hospital
days is more difﬁcult to interpret. Although this might suggest
that “hyperkalemia in primary care” is a less severe condition,
our analysis immanently selects for patients who are not sick
enough to be hospitalized on the hyperkalemia index day
(unfortunately, we had only data on hyperkalemia test dates,
not on the caregiver requesting the test). Finally, methods
for blood potassium analysis have not been uniform in all
laboratories over the entire study period, including both serum-
and plasma-based tests over the years, which is an inevitable
limitation. False-positive hyperkalemia was presumably rare
because all laboratories took various precautions to avoid
falsely elevated potassium values, which included nonreporting
of potassium values in the presence of hemolysis.
The validity of medical diagnoses and disease algorithms
that we used in our study has been documented as high.21
Data on diagnoses set by general practitioners were not
available, only general practitioner prescribed drugs, and our
data thus may have been incomplete for less severe lifestyle-
treated conditions followed up in primary care. Because all
reimbursed prescriptions have to be redeemed at pharmacies
in Denmark, obtaining drugs from other sources is unlikely.
Nonetheless, prescription redemption is only a marker of
consumption of any drug and noncompliance is possible.
Conclusion
In this study, a substantial proportion of patients with HF
developed hyperkalemia, and recurrences were common. In
particular, those with kidney disease and those treated with
spironolactone were at high risk. Hyperkalemia was associated
with severe clinical outcomes and death in patients with HF.
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Table S1. Codes used to identify study variables. 
 Algorithm 
Heart failure ICD-8: 427.0, 427.1 
ICD-10: I50, I110, I130, I132 
Cardiomyopathy ICD-10: I42 
Valvular heart disease ICD-10: I00-I02, I05-I09, I34, I35, I36, I37, Q20-Q25, Q22, Q23 
Myocardial infarction ICD-10: I21;I22;I23 
Atrial fibrillation or flutter 
Echocardiography 
ICD-10: I48 
UXUC80  
Diabetes defined as a previous hospitalization with a hospital diagnosis of 
diabetes (ICD-8 259-250; ICD-10 E10-E14, H360), or at least 
one previous prescription for a glucose-lowering drug (ATC code 
A10), or presence of two occurrences of a HbA1c measurement > 
6.5% 
Chronic kidney disease Defined as either a previous hospitalization with a hospital 
diagnosis of chronic nephritic syndrome (N03), glomerular 
disease (N08), chronic kidney disease / chronic renal failure 
(N18-N19), diabetic nephropathy (E102, E112, E122, E132, 
E142), or hypertension with renal failure (I120, I131, I132); or a 
previous  dialysis procedure (BJFD2); or presence of two 
occurrences more than 90 days apart of a creatinine measurement 
corresponding to an eGFR <60 mL/min/1.73m2 
Hypertension defined as a previous hospitalization with a hospital diagnosis of 
hypertension (I10-I15) or a previous prescription for at least two 
of the following classes of antihypertensive drugs: adrenergic 
blockers and others (C02), non-loop diuretics (C03A, C03B, 
C03D, C03E), β blockers (C07), calcium channel blockers (C08), 
RAAS inhibitors (C09) 
Peripheral vascular disease ICD-10: I70; I71; I72; I73; I74; I77 
Cerebrovascular disease ICD-10: I60-I69; G45; G46 
Chronic pulmonary disease ICD-10: J40-J47; J60-J67; J68.4; J70.1; J70.3; J84.1; J92.0; 
J96.1; J98.2; J98.3 
Peptic ulcer disease ICD-10: K22.1; K25-K28 
Any malignant disease ICD-10: C00-C96 
Alcoholism-related or other 
substance-abuse related 
disorders 
ICD-10: T36-T65; F10-F19; G312; G621; G721; I 426; K292; 
K860; K70; R780; T51; Z714; Z721 
Medical obesity ICD-10: E65-E66 
ACEis ATC: C09A, C09B 
ARBs ATC: C09C, C09D 
Beta-blockers ATC: C07 
Potassium-sparing diuretics 
(spironolactone etc.) 
ATC: C03D, C03E 
Non-steroidal inflammatory 
drugs 
ATC:M01A 
Macrolides J01FA 
Trimethoprim J01EA, J01EE 
D
ow
nloaded from
 http://ahajournals.org by on May 7, 2019
 
 
Potassium supplements ATC: A12B 
Hospitalization with any 
cardiac diagnoses 
ICD-10: DI00-DI99 
Hospitalization with 
ventricular arrhythmia 
ICD-10: DI47, DI49 
Hospitalization with cardiac 
arrest 
ICD-10: DI46 
Hospitalization with ICU 
admission 
Codes: NABE, NABB 
Hospitalization with dialysis 
procedure 
Codes: BJFD2 
Hospitalization with ventilator 
treatment 
Codes: BGDA0 
Hyperkalemia Code NPU03230. Analysis numbers AAA00958, 110262, 
111262 115230, 115231, 1511140, 1610147, 1613230, 1710304, 
1713230, 1813230, 1817159, 1311140, 1411140 
 
Abbreviations: ATC, anatomical therapeutic chemical classification; ICD, international classification of diseases
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Table S2. Baseline characteristics of patients with incident heart failure in Northern Denmark, 2000-2012. Incidences of any (>5.0 mmol/L), 
moderate (>5.5 mmol/L), and severe (>6.0 mmol/L) hyperkalemia (HK) events are shown according to each characteristic. 
 
Hyperkalemia event is defined as >5.0 mmol/L 
 
 
Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-years 
(95% CI) 
1-year cumulative 
incidence proportion 
of HK (95% CI) 
3-year cumulative 
incidence proportion 
of HK (95% CI) 
 Total number 31,649 (100%) 0.34 8 69.32 0.86 178.02 (174.89-
181.19) 
25.2 (24.5-25.8) 32.1 (31.4-32.9) 
Year of diagnosis          
 2000-2006 19,286 (60.9%) 0.64 8 53.03 1.14 147.24 (144.00-
150.55) 
22.6 (21.8-23.4) 30.3 (29.4-31.2) 
 2007-2012 12,363 (39.1%) 0.14 7 16.28 0.59 278.25 (270.21-
286.47) 
29.1 (28.0-30.3) 35.0 (33.7-36.3) 
Sex          
 Women 14,809 (46.8%) 0.32 7 31.70 0.80 178.88 (174.26-
183.60) 
24.6 (23.7-25.5) 31.5 (30.4-32.6) 
 Men 16,840 (53.2%) 0.35 8 37.62 0.91 177.29 (173.06-
181.60) 
25.7 (24.8-26.5) 32.7 (31.6-33.7) 
Age at diagnosis, 
years 
         
 Median (quartiles) 78 (69.1-84.9)        
 <18 80 (0.3%) 0.06 1 0.24 0.41 161.39 (114.21-
221.52) 
41.3 (22.9-59.6) 43.8 (24.4-63.1) 
 18-44 582 (1.8%) 0.31 9 2.11 2.36 99.69 (86.66-114.12) 23.2 (18.7-27.7) 28.0 (22.9-33.1) 
 45-59 2,851 (9.0%) 0.47 9 10.83 2.54 95.61 (89.87-101.61) 21.4 (19.5-23.3) 27.8 (25.6-30.1) 
 60-69 5,044 (15.9%) 0.47 9 14.91 1.63 146.97 (140.88-
153.26) 
26.1 (24.4-27.7) 33.8 (31.8-35.8) 
 70-79 9,376 (29.6%) 0.45 9 21.54 0.98 185.23 (179.52-
191.06) 
26.2 (25.0-27.4) 33.9 (32.5-35.4) 
 >=80 13,716 (43.3%) 0.21 6 19.70 0.44 247.51 (240.61-
254.56) 
24.9 (23.9-25.9) 31.3 (30.2-32.5) 
Lowest level of eGFR measured 
before hyperkalemia/index date 
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Hyperkalemia event is defined as >5.0 mmol/L 
 
 
Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-years 
(95% CI) 
1-year cumulative 
incidence proportion 
of HK (95% CI) 
3-year cumulative 
incidence proportion 
of HK (95% CI) 
 No values below 
60 mL/min/1.73m2 
7,679 (24.3%) 0.53 9 21.52 1.65 125.74 (121.05-
130.57) 
21.3 (20.1-22.4) 28.5 (27.1-29.9) 
 eGFR 45-59 
mL/min/1.73m2 
6,931 (21.9%) 0.43 9 15.24 0.98 189.28 (182.44-
196.32) 
26.1 (24.7-27.5) 34.5 (32.8-36.2) 
 eGFR 30-44 
mL/min/1.73m2 
5,800 (18.3%) 0.19 7 8.67 0.40 325.49 (313.60-
337.73) 
35.0 (33.1-36.9) 43.4 (41.2-45.7) 
 eGFR 15-29 
mL/min/1.73m2 
3,707 (11.7%) 0.08 5 3.48 0.15 569.77 (544.97-
595.40) 
43.6 (40.8-46.5) 50.6 (47.4-53.9) 
 eGFR<15 
mL/min/1.73m2 
1,166 (3.7%) 0.07 6 0.82 0.10 786.16 (726.47-
849.45) 
48.1 (42.6-53.6) 52.9 (46.8-59.0) 
 Dialysis 298 (0.9%) 0.17 8 0.20 0.20 827.42 (706.69-
962.87) 
47.7 (36.8-58.5) 55.0 (42.5-67.6) 
 No eGFR 
recorded 
6,068 (19.2%) 3.91 7 19.39 1.92 58.49 (55.14-62.00) 2.8 (2.4-3.2) 6.9 (6.2-7.6) 
Conditions underlying heart failure         
 Cardiomyopathy  1,341 (4.2%) 0.38 8 3.61 1.41 153.73 (141.21-
167.07) 
26.8 (23.5-30.0) 34.1 (30.2-37.9) 
 Valvular heart 
disease  
4,262 (13.5%) 0.25 8 7.67 0.59 236.90 (226.13-
248.04) 
29.8 (27.8-31.8) 36.7 (34.5-39.0) 
 Myocardial 
infarction  
6,787 (21.4%) 0.36 8 14.43 0.82 192.57 (185.48-
199.87) 
26.43 (25.01-27.86) 34.18 (32.47-35.90) 
 Ischemic heart 
disease 
12,734 (40.2%) 0.33 8 27.37 0.80 189.95 (184.82-
195.18) 
26.7 (25.6-27.7) 34.1 (32.9-35.4) 
 Atrial fibrillation  11,094 (35.1%) 0.38 8 23.60 0.88 183.59 (178.16-
189.14) 
25.1 (24.0-26.1) 32.0 (30.8-33.3) 
          
Other 
comorbidities 
         
 Diabetes 6,076 (19.2%) 0.25 7 10.12 0.53 292.43 (281.99-
303.16) 
33.7 (31.9-35.5) 42.0 (39.9-44.1) 
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Hyperkalemia event is defined as >5.0 mmol/L 
 
 
Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-years 
(95% CI) 
1-year cumulative 
incidence proportion 
of HK (95% CI) 
3-year cumulative 
incidence proportion 
of HK (95% CI) 
 Chronic kidney 
disease 
12,995 (41.1%) 0.16 7 17.89 0.34 352.13 (343.48-
360.93) 
36.0 (34.7-37.3) 44.1 (42.6-45.6) 
 Hypertension 19,581 (61.9%) 0.32 8 39.23 0.75 207.92 (203.43-
212.48) 
27.4 (26.5-28.3) 35.1 (34.0-36.1) 
 Peripheral 
vascular disease 
3,673 (11.6%) 0.24 8 5.50 0.47 294.47 (280.31-
309.16) 
31.55 (29.36-33.75) 38.77 (36.20-41.34) 
 Cerebrovascular 
disease 
5,489 (17.3%) 0.26 7 9.02 0.52 225.12 (215.44-
235.13) 
25.49 (23.94-27.03) 32.17 (30.35-34.00) 
 Chronic 
pulmonary 
disease 
5,838 (18.4%) 0.30 8 9.96 0.63 238.30 (228.81-
248.09) 
27.18 (25.62-28.75) 34.58 (32.72-36.45) 
 Peptic ulcer 
disease 
3,029 (9.6%) 0.24 8 4.96 0.48 249.32 (235.62-
263.61) 
28.62 (26.37-30.88) 35.42 (32.79-38.06) 
 Any malignant 
disease 
4,778 (15.1%) 0.21 7 6.78 0.41 261.51 (249.48-
273.97) 
26.6 (24.9-28.3) 32.8 (30.8-34.8) 
 Alcoholism-related 
disorders 
2,420 (7.6%) 0.27 8 4.56 0.71 225.82 (212.23-
240.05) 
29.3 (26.7-31.8) 36.7 (33.7-39.7) 
 Medical obesity 2,159 (6.8%) 0.40 9 5.13 1.12 190.21 (178.46-
202.53) 
28.3 (25.7-31.0) 36.7 (33.5-39.9) 
Drug treatment 
before first 
admission 
         
 ACEis overall 7,430 (23.5%) 0.29 7 14.20 0.75 224.90 (217.17-
232.84) 
29.0 (27.6-30.5) 36.8 (35.1-38.5) 
 Ramipril 2,714 (8.6%) 0.21 7 4.80 0.67 242.45 (228.72-
256.80) 
30.8 (28.3-33.3) 38.1 (35.1-41.0) 
 Enalapril 2,077 (6.6%) 0.30 8 3.62 0.65 259.35 (243.03-
276.47) 
31.7 (28.8-34.6) 40.0 (36.5-43.5) 
 Other ACEis 2,271 (7.2%) 0.56 8 5.24 1.01 180.43 (169.11-
192.31) 
24.0 (21.7-26.4) 32.4 (29.6-35.3) 
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Hyperkalemia event is defined as >5.0 mmol/L 
 
 
Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-years 
(95% CI) 
1-year cumulative 
incidence proportion 
of HK (95% CI) 
3-year cumulative 
incidence proportion 
of HK (95% CI) 
 ACEis/diuretics 
combination 
1,129 (3.6%) 0.23 8 2.13 0.77 212.13 (193.01-
232.65) 
27.4 (23.8-31.0) 34.4 (30.1-38.6) 
 ARBs overall 3,403 (10.8%) 0.27 8 6.35 0.75 230.84 (219.18-
242.97) 
29.8 (27.6-32.0) 37.3 (34.7-39.9) 
 Losartan 1,437 (4.5%) 0.25 8 2.65 0.73 209.33 (192.26-
227.51) 
27.1 (24.0-30.3) 32.8 (29.2-36.4) 
 Candesartan 579 (1.8%) 0.29 7 1.03 0.77 300.13 (267.65-
335.47) 
37.1 (30.9-43.4) 47.8 (40.0-55.6) 
 Other ARBs 512 (1.6%) 0.25 7 1.03 0.82 243.75 (214.52-
275.84) 
34.2 (27.9-40.4) 43.4 (35.8-50.9) 
 ARBs/diuretics 
combination 
1,129 (3.6%) 0.23 8 2.13 0.77 212.13 (193.01-
232.65) 
27.4 (23.8-31.0) 34.4 (30.1-38.6) 
 Beta-blockers 9,742 (30.8%) 0.33 8 20.27 0.88 190.75 (184.78-
196.86) 
26.0 (24.8-27.2) 33.1 (31.7-34.5) 
 Spironolactone 3,451 (10.9%) 0.26 7 6.09 0.55 240.43 (228.27-
253.07) 
28.7 (26.6-30.8) 36.4 (33.8-38.9) 
 Potassium 
supplements 
9,537 (30.1%) 0.28 8 16.54 0.60 219.95 (212.86-
227.22) 
25.4 (24.2-26.6) 32.1 (30.7-33.5) 
 Loop diuretics  12,484 (39.4%) 0.28 8 20.86 0.56 243.39 (236.74-
250.18) 
27.4 (26.3-28.5) 34.7 (33.4-36.0) 
 NSAIDs 7,076 (22.4%) 0.35 8 15.46 0.93 178.24 (171.64-
185.02) 
25.0 (23.7-26.4) 31.9 (30.3-33.5) 
 Trimetoprim 798 (2.5%) 0.16 6 1.07 0.38 242.70 (214.04-
274.13) 
24.4 (20.5-28.4) 29.2 (24.7-33.7) 
 Macrolides   3,774 (11.9%) 0.36 8 7.40 0.81 197.80 (187.80-
208.20) 
25.1 (23.3-27.0) 32.5 (30.3-34.8) 
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Hyperkalemia event is defined as >5.5 mmol/L 
  Number 
Median 
years to 
first HK 
event  
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK per 
1,000 person-years 
(95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence proportion of 
HK (95% CI) 
 Total 31,649 (100%) 0.61 11 85.87 1.46 72.48 (70.69-74.30) 11.2 (10.8-11.6) 15.3 (14.9-15.8) 
Year of 
diagnosis 
         
 2000-2006 19,286 (60.9%) 1.15 13 65.67 1.94 61.33 (59.45-63.26) 10.0 (9.5-10.4) 14.4 (13.8-15.0) 
 2007-2012 12,363 (39.1%) 0.19 9 20.20 1.02 108.73 (104.23-113.38) 13.2 (12.5-13.8) 16.8 (16.0-17.6) 
Sex          
 Women 14,809 (46.8%) 0.57 11 38.86 1.33 73.80 (71.12-76.55) 11.1 (10.6-11.7) 15.1 (14.5-15.8) 
 Men 16,840 (53.2%) 0.64 12 47.01 1.58 71.39 (69.00-73.85) 11.3 (10.7-11.8) 15.5 (14.8-16.1) 
Age at 
diagnosis, 
years 
         
 Median (quartiles) 78 (69.1-84.9)        
 <18 80 (0.3%) 0.08 3 0.30 2.32 83.16 (53.82-122.76) 26.3 (13.2-39.3) 31.3 (16.5-46.0) 
 18-44 582 (1.8%) 0.22 12 2.61 3.64 37.96 (30.85-46.21) 11.7 (8.7-14.6) 14.4 (11.1-17.8) 
 45-59 2,851 (9.0%) 0.81 14 13.04 3.65 39.42 (36.08-42.98) 9.3 (8.2-10.5) 13.0 (11.6-14.4) 
 60-69 5,044 (15.9%) 1.06 15.5 19.02 2.75 58.26 (54.88-61.79) 10.8 (9.8-11.7) 15.3 (14.2-16.5) 
 70-79 9,376 (29.6%) 0.84 13 27.15 1.74 75.37 (72.13-78.70) 11.7 (10.9-12.4) 16.2 (15.3-17.1) 
 >=80 13,716 (43.3%) 0.34 8 23.76 0.73 102.37 (98.35-106.53) 11.3 (10.7-11.9) 15.1 (14.4-15.8) 
Lowest level of eGFR measured 
before hyperkalemia/index date 
        
 No values below 
60 mL/min/1.73m2 
7,679 (24.3%) 1.13 16 26.56 2.49 42.73 (40.28-45.29) 7.1 (6.5-7.7) 10.7 (9.9-11.5) 
 eGFR 45-59 
mL/min/1.73m2 
6,931 (21.9%) 0.87 13 19.93 1.74 68.49 (64.90-72.22) 10.3 (9.5-11.1) 14.6 (13.7-15.6) 
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Hyperkalemia event is defined as >5.5 mmol/L 
  Number 
Median 
years to 
first HK 
event  
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK per 
1,000 person-years 
(95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence proportion of 
HK (95% CI) 
 eGFR 30-44 
mL/min/1.73m2 
5,800 (18.3%) 0.47 11 11.89 0.94 123.85 (117.60-130.34) 15.7 (14.6-16.8) 21.0 (19.6-22.3) 
 eGFR 15-29 
mL/min/1.73m2 
3,707 (11.7%) 0.16 8 5.02 0.38 234.43 (221.22-248.21) 23.3 (21.5-25.1) 29.4 (27.3-31.5) 
 eGFR<15 
mL/min/1.73m2 
1,166 (3.7%) 0.08 8 1.18 0.20 367.93 (334.09-404.28) 30.4 (26.6-34.2) 35.1 (30.9-39.3) 
 Dialysis 298 (0.9%) 0.25 11 0.28 0.33 465.87 (388.95-553.55) 32.6 (24.7-40.4) 41.3 (31.8-50.8) 
 No eGFR 
measurement 
recorded 
6,068 (19.2%) 4.29 12 21.02 2.12 24.41 (22.34-26.62) 1.0 (0.8-1.3) 2.9 (2.5-3.3) 
Conditions underlying heart 
failure 
        
 Cardiomyopathy  1,341 (4.2%) 0.79 13 4.64 2.40 60.34 (53.48-67.83) 11.3 (9.4-13.2) 16.0 (13.6-18.3) 
 Valvular heart 
disease  
4,262 (13.5%) 0.41 11 9.76 1.07 98.35 (92.23-104.78) 14.1 (12.9-15.4) 18.5 (17.0-19.9) 
 Myocardial 
infarction 
6,787 (21.4%) 0.65 12 18.14 1.42 79.53 (75.48-83.75) 12.05 (11.17-12.93) 16.71 (15.64-17.77) 
 Ischemic heart 
disease 
12,734 (40.2%) 0.58 12 34.65 1.43 76.05 (73.17-79.01) 11.9 (11.3-12.6) 16.3 (15.5-17.0) 
 Atrial fibrillation  11,094 (35.1%) 0.61 12 28.86 1.46 74.54 (71.42-77.76) 11.1 (10.4-11.8) 15.2 (14.4-16.0) 
          
Other 
comorbidities 
         
 Diabetes 6,076 (19.2%) 0.55 11 13.28 1.06 127.39 (121.39-133.61) 16.5 (15.4-17.6) 22.5 (21.2-23.9) 
 Chronic kidney 
disease 
12,995 (41.1%) 0.31 10 24.61 0.77 141.92 (137.25-146.70) 17.7 (16.9-18.5) 23.3 (22.4-24.3) 
 Hypertension 19,581 (61.9%) 0.56 11 49.27 1.33 86.38 (83.80-89.01) 12.7 (12.1-13.2) 17.4 (16.7-18.0) 
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Hyperkalemia event is defined as >5.5 mmol/L 
  Number 
Median 
years to 
first HK 
event  
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK per 
1,000 person-years 
(95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence proportion of 
HK (95% CI) 
 Peripheral vascular 
disease 
3,673 (11.6%) 0.41 11 7.14 0.84 123.20 (115.19-131.61) 15.38 (14.00-16.76) 20.09 (18.47-21.71) 
 Cerebrovascular 
disease 
5,489 (17.3%) 0.47 11 11.14 0.90 93.39 (87.80-99.24) 11.55 (10.59-12.51) 15.56 (14.42-16.69) 
 Chronic pulmonary 
disease 
5,838 (18.4%) 0.64 12 12.61 1.06 99.52 (94.09-105.18) 12.35 (11.39-13.31) 17.37 (16.19-18.55) 
 Peptic ulcer 
disease 
3,029 (9.6%) 0.48 11 6.27 0.90 103.61 (95.80-111.89) 13.04 (11.66-14.42) 17.63 (15.98-19.28) 
 Any malignant 
disease 
4,778 (15.1%) 0.38 10 8.49 0.69 108.75 (101.84-115.99) 12.4 (11.3-13.4) 16.4 (15.2-17.7) 
 Alcoholism-related 
disorders 
2,420 (7.6%) 0.41 11 5.79 1.20 95.07 (87.29-103.36) 14.0 (12.4-15.7) 18.9 (17.0-20.9) 
 Medical obesity 2,159 (6.8%) 0.92 15 6.44 1.85 89.88 (82.71-97.51) 13.8 (12.1-15.5) 20.2 (18.1-22.3) 
Drug treatment before first 
admission 
        
 ACEis overall 7,430 (23.5%) 0.50 11 17.94 1.36 92.24 (87.85-96.80) 13.4 (12.5-14.2) 18.1 (17.0-19.2) 
 Ramipril 2,714 (8.6%) 0.35 10 6.12 1.30 97.15 (89.50-105.28) 14.0 (12.5-15.5) 18.6 (16.8-20.4) 
 Enalapril 2,077 (6.6%) 0.47 11 4.66 1.24 107.41 (98.21-117.24) 14.8 (13.0-16.6) 20.2 (18.0-22.3) 
 Other ACEis 2,271 (7.2%) 0.95 13 6.50 1.70 73.73 (67.27-80.63) 10.7 (9.3-12.2) 15.4 (13.7-17.2) 
 ACEis/diuretics 
combination 
731 (2.3%) 0.23 10 1.56 1.35 109.06 (93.28-126.74) 16.0 (12.8-19.2) 20.5 (16.8-24.2) 
 ARBs 3,403 (10.8%) 0.44 11 8.02 1.30 98.72 (91.96-105.84) 14.4 (13.0-15.8) 19.5 (17.9-21.2) 
 Losartan 1,437 (4.5%) 0.42 12 3.24 1.12 90.94 (80.86-101.93) 13.1 (11.1-15.1) 16.8 (14.5-19.1) 
 Candesartan 579 (1.8%) 0.68 12 1.45 1.78 120.62 (103.41-139.88) 17.1 (13.4-20.8) 25.6 (20.8-30.3) 
 Other ARBs 512 (1.6%) 0.40 8.5 1.33 1.73 102.10 (85.66-120.78) 16.6 (12.7-20.5) 23.0 (18.3-27.8) 
 ARBs/diuretics 
combination 
1,129 (3.6%) 0.44 12 2.59 1.25 95.59 (84.06-108.25) 13.8 (11.5-16.2) 18.4 (15.7-21.2) 
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Hyperkalemia event is defined as >5.5 mmol/L 
  Number 
Median 
years to 
first HK 
event  
Median 
number of 
measurements 
before the first 
HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK per 
1,000 person-years 
(95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence proportion of 
HK (95% CI) 
 Beta-blockers 9,742 (30.8%) 0.51 11 24.83 1.45 78.95 (75.49-82.52) 12.0 (11.3-12.8) 16.4 (15.5-17.3) 
 Spironolactone 3,451 (10.9%) 0.43 10 7.66 1.01 104.48 (97.36-111.97) 14.3 (12.9-15.6) 19.0 (17.4-20.6) 
 Potassium 
supplements 
9,537 (30.1%) 0.48 11 20.23 0.96 93.74 (89.57-98.06) 12.1 (11.4-12.9) 16.2 (15.3-17.1) 
 Loop diuretics  12,484 (39.4%) 0.48 11 25.93 0.94 106.00 (102.07-110.04) 13.4 (12.7-14.1) 18.0 (17.2-18.9) 
 NSAIDs 7,076 (22.4%) 0.62 11 19.11 1.56 73.10 (69.32-77.04) 11.5 (10.7-12.3) 15.3 (14.3-16.3) 
 Trimetoprim 798 (2.5%) 0.16 8 1.27 0.65 107.33 (90.05-126.96) 12.2 (9.6-14.7) 14.8 (11.9-17.7) 
 Macrolides   3,774 (11.9%) 0.60 12 9.17 1.28 82.74 (76.96-88.85) 11.8 (10.6-12.9) 16.1 (14.7-17.5) 
 
 
 
  D
ow
nloaded from
 http://ahajournals.org by on May 7, 2019
  
 
 
Hyperkalemia event is defined as >6.0 mmol/L 
  Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurement
s before the 
first HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-
years (95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence 
proportion of HK 
(95% CI) 
 Total 31,649 (100%) 0.84 14 92.43 1.73 31.74 (30.61-32.91) 4.9 (4.7-5.2) 7.0 (6.7-7.3) 
Year of diagnosis          
 2000-2006 19,286 (60.9%) 1.45 16 70.65 2.30 26.93 (25.74-28.17) 4.3 (4.0-4.6) 6.4 (6.1-6.8) 
 2007-2012 12,363 (39.1%) 0.27 11 21.77 1.21 47.35 (44.51-50.33) 5.9 (5.5-6.3) 7.8 (7.3-8.3) 
Sex          
 Women 14,809 (46.8%) 0.86 14 41.80 1.59 32.80 (31.09-34.59) 4.9 (4.5-5.3) 6.9 (6.5-7.4) 
 Men 16,840 (53.2%) 0.83 14 50.63 1.85 30.87 (29.36-32.44) 4.9 (4.6-5.3) 7.0 (6.6-7.4) 
Age at diagnosis, 
years 
         
 Median 
(quartiles) 
78 (69.1-84.9)        
 <18 80 (0.3%) 0.05 1 0.34 3.88 40.65 (22.22-68.20) 15.0 (5.8-24.2) 17.5 (7.4-27.6) 
 18-44 582 (1.8%) 0.28 12.5 2.77 4.07 18.79 (14.03-24.64) 6.0 (4.0-8.1) 7.6 (5.2-9.9) 
 45-59 2,851 (9.0%) 1.22 20 13.85 4.15 18.41 (16.22-20.81) 4.1 (3.4-4.9) 6.0 (5.1-6.9) 
 60-69 5,044 (15.9%) 1.48 22 20.55 3.16 26.66 (24.48-28.99) 4.8 (4.1-5.4) 7.2 (6.4-7.9) 
 70-79 9,376 (29.6%) 1.03 16 29.50 2.07 32.14 (30.12-34.25) 5.0 (4.5-5.4) 7.3 (6.7-7.8) 
 >=80 13,716 (43.3%) 0.42 10 25.41 0.86 43.96 (41.42-46.62) 5.0 (4.6-5.4) 6.8 (6.4-7.3) 
Lowest level of eGFR measured 
before hyperkalemia/index date 
        
 No values 
below 60 
mL/min/1.73m2 
7,679 (24.3%) 1.50 20 28.07 2.75 17.49 (15.98-19.11) 2.7 (2.3-3.1) 4.3 (3.9-4.8) 
 eGFR 45-59 
mL/min/1.73m2 
6,931 (21.9%) 1.30 16 21.71 2.05 27.32 (25.16-29.61) 3.8 (3.4-4.3) 5.9 (5.3-6.5) 
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Hyperkalemia event is defined as >6.0 mmol/L 
  Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurement
s before the 
first HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-
years (95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence 
proportion of HK 
(95% CI) 
 eGFR 30-44 
mL/min/1.73m2 
5,800 (18.3%) 0.70 13 13.38 1.23 51.43 (47.66-55.42) 6.7 (6.0-7.4) 9.3 (8.5-10.2) 
 eGFR 15-29 
mL/min/1.73m2 
3,707 (11.7%) 0.22 9 5.91 0.54 102.08 (94.09-
110.56) 
11.7 (10.5-12.9) 15.1 (13.7-16.4) 
 eGFR<15 
mL/min/1.73m2 
1,166 (3.7%) 0.09 8 1.45 0.31 161.19 (141.16-
183.27) 
15.7 (13.2-18.2) 18.6 (15.9-21.4) 
 Dialysis 298 (0.9%) 0.38 14 0.38 0.57 213.80 (169.79-
265.73) 
18.5 (13.1-23.9) 24.2 (17.8-30.6) 
 No eGFR 
recorded 
6,068 (19.2%) 4.48 17 21.54 2.16 11.38 (10.00-12.89) 0.4 (0.2-0.6) 1.3 (1.0-1.5) 
Conditions 
underlying heart 
failure 
         
 Cardiomyopathy  1,341 (4.2%) 1.23 15 4.96 2.69 25.99 (21.70-30.88) 4.4 (3.3-5.5) 7.3 (5.8-8.8) 
 Valvular heart 
disease  
4,262 (13.5%) 0.59 13 10.64 1.30 42.57 (38.74-46.68) 6.4 (5.6-7.2) 8.7 (7.8-9.7) 
 Myocardial 
infarction  
6,787 (21.4%) 0.75 13 19.63 1.72 34.74 (32.18-37.45) 5.55 (4.98-6.13) 7.59 (6.91-8.27) 
 Ischemic heart 
disease 
12,734 (40.2%) 0.77 14 37.55 1.74 32.39 (30.59-34.26) 5.2 (4.8-5.6) 7.2 (6.7-7.7) 
 Atrial fibrillation  11,094 (35.1%) 0.86 17 31.08 1.72 31.79 (29.84-33.84) 4.7 (4.3-5.1) 6.7 (6.2-7.2) 
          
Comorbidities          
 Diabetes 6,076 (19.2%) 0.75 15 14.85 1.34 59.25 (55.40-63.29) 8.0 (7.3-8.8) 11.4 (10.5-12.3) 
 Chronic kidney 
disease 
12,995 (41.1%) 0.47 13 27.68 1.02 61.56 (58.67-64.55) 8.1 (7.6-8.6) 11.0 (10.4-11.6) 
 Hypertension 19,581 (61.9%) 0.75 14 53.42 1.61 38.41 (36.77-40.11) 5.7 (5.3-6.0) 8.1 (7.7-8.5) 
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Hyperkalemia event is defined as >6.0 mmol/L 
  Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurement
s before the 
first HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-
years (95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence 
proportion of HK 
(95% CI) 
 Peripheral 
vascular 
disease 
3,673 (11.6%) 0.54 15 7.89 1.05 52.22 (47.30-57.51) 6.70 (5.83-7.56) 9.34 (8.30-10.38) 
 Cerebrovascula
r disease 
5,489 (17.3%) 0.59 13 12.01 1.08 39.89 (36.40-43.63) 5.03 (4.42-5.64) 6.83 (6.12-7.55) 
 Chronic 
pulmonary 
disease 
5,838 (18.4%) 0.81 14 13.71 1.25 43.26 (39.84-46.88) 5.55 (4.93-6.17) 7.85 (7.10-8.59) 
 Peptic ulcer 
disease 
3,029 (9.6%) 0.59 14 6.88 1.12 46.94 (41.96-52.34) 6.14 (5.23-7.05) 8.75 (7.65-9.85) 
 Any malignant 
disease 
4,778 (15.1%) 0.49 12.5 9.17 0.82 49.96 (45.49-54.75) 5.7 (5.0-6.4) 7.9 (7.1-8.7) 
 Alcoholism-
related 
disorders 
2,420 (7.6%) 0.55 14 6.33 1.51 46.11 (40.97-51.71) 7.2 (6.1-8.3) 9.7 (8.4-11.0) 
 Medical obesity 2,159 (6.8%) 1.08 21 7.13 2.23 41.78 (37.17-46.81) 6.7 (5.5-7.8) 10.2 (8.8-11.7) 
Drug treatment 
before first 
admission 
         
 ACEis overall 7,430 (23.5%) 0.54 13 19.51 1.65 41.72 (38.90-44.69) 6.4 (5.8-7.0) 8.7 (8.0-9.4) 
 Ramipril 2,714 (8.6%) 0.44 12 6.63 1.52 42.25 (37.44-47.49) 6.6 (5.6-7.6) 8.7 (7.5-9.8) 
 Enalapril 2,077 (6.6%) 0.57 15 5.13 1.52 49.74 (43.82-56.24) 7.0 (5.8-8.2) 9.9 (8.5-11.3) 
 Other ACEis 2,271 (7.2%) 1.00 15 7.04 2.03 33.25 (29.12-37.79) 5.2 (4.2-6.1) 7.2 (6.1-8.4) 
 ACEis/diuretics 
combination 
731 (2.3%) 0.28 12 1.72 1.62 50.45 (40.41-62.24) 7.8 (5.7-9.9) 10.3 (7.8-12.7) 
 ARBs overall 3,403 (10.8%) 0.63 14 8.87 1.68 41.03 (36.92-45.47) 6.3 (5.4-7.1) 8.6 (7.6-9.7) 
 Losartan 1,437 (4.5%) 0.42 14 3.53 1.33 37.69 (31.56-44.67) 6.1 (4.7-7.4) 7.3 (5.9-8.8) 
 Candesartan 579 (1.8%) 0.70 14 1.67 2.19 47.87 (37.96-59.57) 7.6 (5.3-9.9) 11.4 (8.5-14.3) 
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Hyperkalemia event is defined as >6.0 mmol/L 
  Number 
Median 
years to 
first HK 
event 
Median 
number of 
measurement
s before the 
first HK event 
Total 
person-
years of 
follow-up 
(1,000) 
Median 
person-
years of 
follow-up 
Incidence rate of HK 
per 1,000 person-
years (95% CI) 
1-year cumulative 
incidence 
proportion of HK 
(95% CI) 
3-year cumulative 
incidence 
proportion of HK 
(95% CI) 
 Other ARBs 512 (1.6%) 0.96 15 1.50 2.25 44.77 (34.70-56.86) 7.0 (4.6-9.4) 10.5 (7.6-13.5) 
 ARBs/diuretics 
combination 
1,129 (3.6%) 0.70 14 2.87 1.66 38.71 (31.85-46.62) 5.3 (3.9-6.7) 7.9 (6.2-9.6) 
 Beta-blockers 9,742 (30.8%) 0.71 14 26.71 1.74 34.86 (32.66-37.17) 5.3 (4.8-5.8) 7.5 (7.0-8.1) 
 Spironolactone 3,451 (10.9%) 0.50 12 8.38 1.30 46.45 (41.94-51.30) 6.6 (5.7-7.5) 9.4 (8.3-10.4) 
 Potassium 
supplements 
9,537 (30.1%) 0.56 13 21.73 1.12 42.88 (40.17-45.72) 5.7 (5.2-6.2) 7.8 (7.2-8.4) 
 Loop diuretics  12,484 (39.4%) 0.56 13 28.16 1.14 48.48 (45.94-51.12) 6.4 (5.9-6.9) 8.8 (8.2-9.3) 
 NSAIDs 7,076 (22.4%) 0.75 13 20.51 1.81 32.03 (29.63-34.58) 5.1 (4.6-5.7) 7.1 (6.5-7.8) 
 Trimetoprim 798 (2.5%) 0.17 10 1.35 0.79 59.28 (47.00-73.77) 6.6 (4.8-8.5) 8.8 (6.6-10.9) 
 Macrolides   3,774 (11.9%) 0.72 15 9.85 1.51 37.65 (33.91-41.68) 5.5 (4.7-6.3) 7.8 (6.9-8.7) 
 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, 
hyperkalemia; NSAIDs, non-steroidal anti-inflammatory drugs. 
. 
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Table S3. Prevalence and prevalence ratios (PR) for risk factors prior to the 
hyperkalemia/index date among heart failure patients with hyperkalemia versus matched 
comparison patients divided in moderate (>5.5 mmol/L) and severe (>6.0 mmol/L) 
hyperkalemia. 
  
Patients with heart 
failure and 
hyperkalemia >5.5 
mmol/L 
 
Matched 
comparisons 
without 
hyperkalemia* 
PR (95% CI) 
 No. of patients  6,224 (100%) 6,130 (100%)  
 Females 2,868 (46.1%) 2,829 (46.2%)  
 Age, median (quartiles), y 79 (70.9-85.2) 79 (71.2-85.2)  
 K+ tests 6 mo. before HK/index 
date, median (quartiles) 
7.0 (2.0-13.0) 2.0 (0.0-6.0)  
 Acute heart failure hospitalizations 
6 mo. before HK/index date 
median (quartiles) 
0.0 (0.0-1.0) 0.0 (0.0-0.0)  
Conditions underlying 
heart failure † 
    
 Cardiomyopathy  487 (7.8%) 440 (7.2%) 1.09 (0.96-1.23) 
 Valvular heart disease  1,205 (19.4%) 903 (14.7%) 1.31 (1.21-1.42) 
 Myocardial infarction  1,881 (30.2%) 1,678 (27.4%) 1.10 (1.0-1.17) 
 Any ischemic heart disease 3,055 (49.1%) 2,779 (45.3%) 1.08 (1.04-1.12) 
 Atrial fibrillation  2,536 (40.7%) 2,359 (38.5%) 1.06 (1.01-1.11) 
     
Lowest level of eGFR 
measured before 
hyperkalemia/index 
date 
    
 No values below 60 
mL/min/1.73m2 
507 (8.1%) 1,195 (19.5%) 0.42 (0.38-0.46) 
 eGFR 45-59 mL/min/1.73m2 855 (13.7%) 1,449 (23.6%) 0.58 (0.54-0.63) 
 eGFR 30-44 mL/min/1.73m2 1,708 (27.4%) 1,428 (23.3%) 1.18 (1.11-1.25) 
 eGFR 15-29 mL/min/1.73m2 2,127 (34.2%) 922 (15.0%) 2.27 (2.12-2.43) 
 eGFR<15 mL/min/1.73m2 742 (11.9%) 212 (3.5%) 3.45 (2.97-4.00) 
 Dialysis 204 (3.3%) 38 (0.6%) 5.29 (3.75-7.46) 
 No eGFR recorded 81 (1.3%) 886 (14.5%) 0.09 (0.07-0.11) 
Selected risk factors 
for hyperkalemia 
    
 Diabetes 2,002 (32.2%) 1,261 (20.6%) 1.56 (1.47-1.66) 
 Chronic kidney disease ‡ 4,650 (74.7%) 3,052 (49.8%) 1.50 (1.46-1.55) 
 Hypertension 5,310 (85.3%) 4,855 (79.2%) 1.08 (1.06-1.10) 
Other comorbidities      
 Peripheral vascular disease 1,167 (18.8%) 764 (12.5%) 1.50 (1.4-1.64) 
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Patients with heart 
failure and 
hyperkalemia >5.5 
mmol/L 
 
Matched 
comparisons 
without 
hyperkalemia* 
PR (95% CI) 
 Cerebrovascular disease 1,335 (21.4%) 1,187 (19.4%) 1.11 (1.0-1.19) 
 Chronic pulmonary disease 1,856 (29.8%) 1,463 (23.9%) 1.25 (1.2-1.33) 
 Peptic ulcer disease 826 (13.3%) 667 (10.9%) 1.22 (1.1-1.34) 
 Any malignant disease 1,159 (18.6%) 928 (15.1%) 1.23 (1.14-1.33) 
 Alcoholism-related disorders 673 (10.8%) 496 (8.1%) 1.34 (1.20-1.49) 
 Medical obesity 678 (10.9%) 445 (7.3%) 1.50 (1.34-1.68) 
Use of specific 
hyperkalemia-
associated 
medications 
    
 ACEis 2,882 (46.3%) 2,637 (43.0%) 1.08 (1.03-1.12) 
 Ramipril 1,416 (22.8%) 1,223 (20.0%) 1.14 (1.07-1.22) 
 Enalapril 691 (11.1%) 550 (9.0%) 1.24 (1.11-1.38) 
 Other ACEis 783 (12.6%) 846 (13.8%) 0.91 (0.83-1.00) 
 ACEis/diuretics combination 165 (2.7%) 132 (2.2%) 1.23 (0.98-1.54) 
 ARBs overall 972 (15.6%) 908 (14.8%) 1.06 (0.98-1.15) 
 Losartan 430 (6.9%) 433 (7.1%) 0.98 (0.86-1.11) 
 Candesartan 230 (3.7%) 189 (3.1%) 1.20 (0.99-1.45) 
 Other ARBs 165 (2.7%) 137 (2.2%) 1.19 (0.95-1.48) 
 ARBs/diuretics combination 229 (3.7%) 242 (3.9%) 0.93 (0.78-1.11) 
 Spironolactone 2,394 (38.5%) 1,523 (24.8%) 1.55 (1.47-1.63) 
 Potassium supplements 3,235 (52.0%) 3,113 (50.8%) 1.02 (0.99-1.06) 
 Loop diuretics 4,401 (70.7%) 3,974 (64.8%) 1.09 (1.06-1.12) 
 NSAIDs 1,416 (22.8%) 1,336 (21.8%) 1.04 (0.98-1.11) 
 Trimetoprim 249 (4.0%) 204 (3.3%) 1.20 (1.00-1.44) 
 Macrolides 883 (14.2%) 709 (11.6%) 1.23 (1.12-1.35) 
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Patients with 
heart failure and 
hyperkalemia >6.0 
mmol/L 
Matched 
comparisons 
without 
hyperkalemia* 
PR (95% CI) 
 No. of patients  2,934 (100%) 2,891 (100%)  
 Females 1,371 (46.7%) 1,353 (46.8%)  
 Age, median (quartiles), y 79 (70.5-85.2) 79 (70.9-85.2)  
 K+ tests 6 mo. before HK/index 
date, median (quartiles) 
7.0 (3.0-15.0) 2.0 (0.0-5.0)  
 Acute heart failure 
hospitalizations 6 mo. before 
HK/index date median 
(quartiles) 
0.0 (0.0-1.0) 0.0 (0.0-0.0)  
Conditions underlying 
heart failure † 
    
 Cardiomyopathy  236 (8.0%) 218 (7.5%) 1.07 (0.89-1.27) 
 Valvular heart disease  591 (20.1%) 441 (15.3%) 1.32 (1.18-1.48) 
 Myocardial infarction  896 (30.5%) 842 (29.1%) 1.05 (1.0-1.13) 
 Any ischemic heart disease 1,455 (49.6%) 1,355 (46.9%) 1.06 (1.00-1.12) 
 Atrial fibrillation  1,227 (41.8%) 1,125 (38.9%) 1.07 (1.01-1.14) 
     
Lowest level of eGFR 
measured before 
hyperkalemia/index 
date 
    
 No values below 60 
mL/min/1.73m2 
179 (6.1%) 526 (18.2%) 0.34 (0.29-0.39) 
 eGFR 45-59 mL/min/1.73m2 291 (9.9%) 632 (21.9%) 0.45 (0.40-0.52) 
 eGFR 30-44 mL/min/1.73m2 707 (24.1%) 725 (25.1%) 0.96 (0.88-1.05) 
 eGFR 15-29 mL/min/1.73m2 1,102 (37.6%) 455 (15.7%) 2.39 (2.17-2.63) 
 eGFR<15 mL/min/1.73m2 482 (16.4%) 115 (4.0%) 4.13 (3.39-5.03) 
 Dialysis 144 (4.9%) 22 (0.8%) 6.45 (4.13-10.07) 
 No eGFR measurements 
recorded 
29 (1.0%) 416 (14.4%) 0.07 (0.05-0.10) 
Selected risk factors 
for hyperkalemia 
    
 Diabetes 1,039 (35.4%) 652 (22.6%) 1.57 (1.44-1.71) 
 Chronic kidney disease ‡ 2,297 (78.3%) 1,480 (51.2%) 1.53 (1.47-1.59) 
 Hypertension 2,562 (87.3%) 2,367 (81.9%) 1.07 (1.04-1.09) 
Other comorbidities      
 Peripheral vascular disease 561 (19.1%) 391 (13.5%) 1.41 (1.3-1.59) 
 Cerebrovascular disease 629 (21.4%) 531 (18.4%) 1.17 (1.1-1.29) 
 Chronic pulmonary disease 901 (30.7%) 702 (24.3%) 1.26 (1.2-1.38) 
 Peptic ulcer disease 424 (14.5%) 307 (10.6%) 1.36 (1.2-1.56) 
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Patients with 
heart failure and 
hyperkalemia >6.0 
mmol/L 
Matched 
comparisons 
without 
hyperkalemia* 
PR (95% CI) 
 Any malignant disease 591 (20.1%) 427 (14.8%) 1.36 (1.22-1.53) 
 Alcoholism-related disorders 372 (12.7%) 245 (8.5%) 1.50 (1.28-1.74) 
 Medical obesity 371 (12.6%) 222 (7.7%) 1.65 (1.41-1.93) 
Use of specific 
hyperkalemia-
associated 
medications 
    
 ACEis overall 1,426 (48.6%) 1,246 (43.1%) 1.13 (1.07-1.19) 
 Ramipril 693 (23.6%) 614 (21.2%) 1.11 (1.01-1.22) 
 Enalapril 369 (12.6%) 243 (8.4%) 1.50 (1.28-1.74) 
 Other ACEis 363 (12.4%) 382 (13.2%) 0.94 (0.82-1.07) 
 ACEis/diuretics combination 83 (2.8%) 58 (2.0%) 1.41 (1.01-1.96) 
 ARBs overall 459 (15.6%) 450 (15.6%) 1.01 (0.89-1.13) 
 Losartan 206 (7.0%) 220 (7.6%) 0.92 (0.77-1.11) 
 Candesartan 108 (3.7%) 83 (2.9%) 1.28 (0.97-1.70) 
 Other ARBs 81 (2.8%) 71 (2.5%) 1.12 (0.82-1.54) 
 ARBs/diuretics combination 97 (3.3%) 124 (4.3%) 0.77 (0.59-1.00) 
 Spironolactone 1,200 (40.9%) 712 (24.6%) 1.66 (1.54-1.79) 
 Potassium supplements 1,586 (54.1%) 1,420 (49.1%) 1.10 (1.05-1.16) 
 Loop diuretics 2,170 (74.0%) 1,837 (63.5%) 1.16 (1.12-1.21) 
 NSAIDs 672 (22.9%) 646 (22.3%) 1.03 (0.93-1.13) 
 Trimetoprim 134 (4.6%) 95 (3.3%) 1.39 (1.07-1.80) 
 Macrolides 456 (15.5%) 332 (11.5%) 1.35 (1.19-1.54) 
 
* Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the 
hyperkalemia/index date 
† As present at the time of heart failure diagnosis.  
‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine 
value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease, see 
text and Supplementary material with codes 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; 
eGFR, estimated Glomerular Filtration Rate; NSAIDs, non-steroidal anti-inflammatory drugs.PR, prevalence ratio
D
ow
nloaded from
 http://ahajournals.org by on May 7, 2019
  
 
 
Table S4. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully matched comparisons without HK 
separate for moderate and (>5.5 mmol/L) and severe (>6.0 mmol/L) HK  
 
 
Heart failure 
patients with first 
HK >5.5 mmol/L 
Matched* heart 
failure 
comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio (95% 
CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  3,975 (4,051.21) 3,170 (1,645.62) 2.03 (1.92-2.14) 1.57 (1.48-1.67) 
Any acute hospitalization  5,117 (7,257.35) 2,484 (1,183.59) 3.92 (3.71-4.14) 2.83 (2.67-3.01) 
Any non-acute hospitalization  1,331 (856.24) 887 (344.90) 2.35 (2.14-2.59) 1.74 (1.55-1.93) 
Any cardiac diagnosis 4,128 (4,219.94) 2,006 (900.10) 3.40 (3.20-3.61) 2.65 (2.49-2.81) 
Ventricular arrhythmia 218 (116.89) 118 (42.12) 2.84 (2.21-3.65) 2.34 (1.77-3.24) 
Cardiac arrest 104 (54.41) 15 (5.30) 11.53 (6.44-20.63) 13.70 (4.02-49.62) 
Dialysis procedure 201 (107.35) 28 (9.90) 2.83 (1.86-4.29) 1.28 (0.78-2.06) 
Ventilator treatment 657 (363.37) 94 (33.35) 11.82 (9.38-14.90) 6.16 (4.28-9.10) 
ICU admission 1,146 (679.53) 247 (88.79) 7.55 (6.50-8.77) 4.74 (3.80-5.99) 
Heart failure re-admission 2,840 (2,176.16) 1,467 (623.56) 2.84 (2.64-3.05) 2.37 (2.20-2.53) 
ACEi prescription  1,867 (1,460.69) 2,461 (1,298.93) 0.98 (0.91-1.05) 0.90 (0.86-0.95) 
ARB prescription 547 (312.83) 780 (305.61) 0.79 (0.70-0.89) 0.93 (0.85-1.01) 
Spironolactone prescription 1,332 (885.95) 1,494 (641.90) 0.87 (0.80-0.94) 0.70 (0.66-0.75) 
Potassium supplement prescription  1,674 (1,170.86) 2,909 (1,625.12) 0.77 (0.72-0.82) 0.66 (0.63-0.70) 
Death 2,887 (1,500.55) 747 (263.52) 4.93 (4.51-5.38) - 
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Heart failure 
patients with first 
HK >6.0 mmol/L 
Matched* heart 
failure 
comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio (95% 
CI)  
Prior-event-rate-
ratio adjusted 
Hazard Ratio 
Any hospital outpatient contact  1,932 (5,256.27) 1,437 (1,559.45) 2.61 (2.40-2.83) 1.96 (1.78-2.14) 
Any acute hospitalization  2,603 (12,392.70) 1,108 (1,085.77) 5.95 (5.47-6.47) 3.68 (3.35-4.02) 
Any non-acute hospitalization  579 (920.35) 390 (317.48) 2.75 (2.36-3.20) 1.86 (1.53-2.15) 
Any cardiac diagnosis 2,078 (5,994.61) 887 (821.60) 4.76 (4.34-5.22) 3.12 (2.85-3.44) 
Ventricular arrhythmia 122 (163.11) 44 (33.14) 5.06 (3.41-7.49) 3.29 (2.04-5.32) 
Cardiac arrest 58 (75.05) 8 (5.98) 13.45 (5.99-30.19) 10.00 (1.36-57.21) 
Dialysis procedure 136 (183.48) 12 (8.97) 4.59 (2.40-8.78) 2.13 (1.05-4.72) 
Ventilator treatment 323 (440.36) 36 (27.01) 18.51 (12.74-26.88) 5.64 (3.19-9.89) 
ICU admission 613 (925.15) 99 (75.17) 12.79 (10.10-16.19) 4.44 (3.12-6.11) 
Heart failure re-admission 1,402 (2,750.84) 624 (546.13) 3.86 (3.46-4.31) 2.88 (2.59-3.21) 
ACEi prescription  723 (1,342.91) 1,162 (1,302.98) 0.78 (0.70-0.87) 0.78 (0.72-0.85) 
ARB prescription 209 (292.88) 395 (329.42) 0.63 (0.52-0.77) 0.87 (0.76-0.99) 
Spironolactone prescription 508 (808.87) 679 (611.97) 0.70 (0.61-0.80) 0.63 (0.57-0.70) 
Potassium supplement prescription  691 (1,162.62) 1,327 (1,536.74) 0.75 (0.67-0.83) 0.64 (0.58-0.69) 
Death 1,608 (2,064.20) 344 (256.73) 6.87 (6.03-7.84) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, see text. 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment regimen, number of acute heart failure hospitalizations 6 
months before the HK/index date, eGFR category, Charlson Comorbidity Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or 
potassium supplements 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios observed 6 months after vs. 6 months before the HK/index 
date,see text 
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Table S5. Chronic heart failure: Baseline characteristics among patients with first hospital diagnosed heart failure, stratified by 
eGFR category and subsequent incidence of hyperkalemia. 
  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Number of HF patients 
(row %) 
2,194 (23.5%) 2,232 (23.9%) 2,043 (21.9%) 1,466 (15.7%) 436 (4.7%) 160 (1.7%) 796 (8.5%) 9,327 (100%) 
 Female 529 (24.1%) 766 (34.3%) 885 (43.3%) 711 (48.5%) 225 (51.6%) 56 (35.0%) 340 (42.7%) 3,512 (37.7%) 
 Median age (quartiles) 64 (55.9-72.8) 71 (63.1-78.6) 77 (69.3-82.7) 79 (71.8-84.9) 78 (69.3-83.6) 69 (58.9-77.2) 76 (66.5-82.1) 73 (63.6-80.8) 
 Echocardiography 
performed before / at 
first HF admission  
2,194 (100%) 2,232 (100%) 2,043 (100%) 1,466 (100%) 436 (100%) 160 (100%) 796 (100%) 9,327 (100%) 
 Heart failure as primary 
diagnosis 
920 (41.9%) 992 (44.4%) 874 (42.8%) 596 (40.7%) 179 (41.1%) 68 (42.5%) 386 (48.5%) 4,015 (43.0%) 
Conditions underlying heart failure †         
 Cardiomyopathy  455 (20.7%) 373 (16.7%) 260 (12.7%) 152 (10.4%) 38 (8.7%) 11 (6.9%) 98 (12.3%) 1,387 (14.9%) 
 Valvular heart disease  289 (13.2%) 376 (16.8%) 443 (21.7%) 366 (25.0%) 93 (21.3%) 27 (16.9%) 122 (15.3%) 1,716 (18.4%) 
 Myocardial infarction  829 (37.8%) 889 (39.8%) 871 (42.6%) 625 (42.6%) 183 (42.0%) 70 (43.8%) 238 (29.9%) 3,705 (39.7%) 
 Any ischemic heart 
disease 
1,246 (56.8%) 1,289 (57.8%) 1,267 (62.0%) 935 (63.8%) 270 (61.9%) 110 (68.8%) 386 (48.5%) 5,503 (59.0%) 
 Atrial fibrillation  807 (36.8%) 991 (44.4%) 985 (48.2%) 701 (47.8%) 204 (46.8%) 52 (32.5%) 370 (46.5%) 4,110 (44.1%) 
          
Other 
comorbidities 
         
 Diabetes 441 (20.1%) 450 (20.2%) 504 (24.7%) 460 (31.4%) 184 (42.2%) 72 (45.0%) 161 (20.2%) 2,272 (24.4%) 
 Chronic kidney 
disease‡ 
20 (0.9%) 957 (42.9%) 1,390 (68.0%) 1,179 (80.4%) 377 (86.5%) 160 (100%) 46 (5.8%) 4,129 (44.3%) 
 Hypertension 2,194 (100%) 2,232 (100%) 2,043 (100%) 1,466 (100%) 436 (100%) 160 (100%) 796 (8.5%) 9,327 (100%) 
 Peripheral vascular 
disease 
191 (8.7%) 258 (11.6%) 329 (16.1%) 294 (20.1%) 110 (25.2%) 62 (38.8%) 85 (10.7%) 1,329 (14.2%) 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Cerebrovascular 
disease 
255 (11.6%) 346 (15.5%) 416 (20.4%) 347 (23.7%) 132 (30.3%) 40 (25.0%) 125 (15.7%) 1,661 (17.8%) 
 Chronic pulmonary 
disease 
340 (15.5%) 405 (18.1%) 392 (19.2%) 358 (24.4%) 113 (25.9%) 26 (16.3%) 115 (14.4%) 1,749 (18.8%) 
 Peptic ulcer disease 143 (6.5%) 177 (7.9%) 184 (9.0%) 216 (14.7%) 60 (13.8%) 31 (19.4%) 64 (8.0%) 875 (9.4%) 
 Any malignant disease 168 (7.7%) 279 (12.5%) 328 (16.1%) 257 (17.5%) 73 (16.7%) 30 (18.8%) 80 (10.1%) 
 
1,215 (13.0%) 
 Alcoholism-related 
disorders 
241 (11.0%) 189 (8.5%) 176 (8.6%) 157 (10.7%) 56 (12.8%) 23 (14.4%) 66 (8.3%) 908 (9.7%) 
 Medical obesity 229 (10.4%) 192 (8.6%) 179 (8.8%) 142 (9.7%) 61 (14.0%) 20 (12.5%) 49 (6.2%) 872 (9.3%) 
Drug treatment, before first admission         
 ACEis overall 1,948 (88.8%) 1,925 (86.2%) 1,633 (79.9%) 1,102 (75.2%) 288 (66.1%) 104 (65.0%) 668 (83.9%) 7,668 (82.2%) 
 Ramipril 1,094 (49.9%) 1,134 (50.8%) 900 (44.1%) 579 (39.5%) 156 (35.8%) 60 (37.5%) 126 (15.8%) 4,049 (43.4%) 
 Enalapril 293 (13.4%) 306 (13.7%) 301 (14.7%) 245 (16.7%) 75 (17.2%) 20 (12.5%) 118 (14.8%) 1,358 (14.6%) 
 Other ACEis 621 (28.3%) 530 (23.7%) 481 (23.5%) 305 (20.8%) 75 (17.2%) 28 (17.5%) 451 (56.7%) 2,491 (26.7%) 
 ACEis/diuretics 
combination 
71 (3.2%) 90 (4.0%) 103 (5.0%) 90 (6.1%) 26 (6.0%) 1 (0.6%) 16 (2.0%) 397 (4.3%) 
 ARBs overall 438 (20.0%) 476 (21.3%) 529 (25.9%) 376 (25.6%) 142 (32.6%) 53 (33.1%) 161 (20.2%) 2,175 (23.3%) 
 Losartan 243 (11.1%) 246 (11.0%) 262 (12.8%) 169 (11.5%) 73 (16.7%) 27 (16.9%) 81 (10.2%) 1,101 (11.8%) 
 Candesartan 88 (4.0%) 110 (4.9%) 111 (5.4%) 56 (3.8%) 36 (8.3%) 24 (15.0%) 25 (3.1%) 450 (4.8%) 
 Other ARBs 54 (2.5%) 57 (2.6%) 82 (4.0%) 61 (4.2%) 18 (4.1%) 5 (3.1%) 30 (3.8%) 307 (3.3%) 
 ARBs/diuretics 
combination 
102 (4.6%) 112 (5.0%) 139 (6.8%) 139 (9.5%) 32 (7.3%) 3 (1.9%) 44 (5.5%) 571 (6.1%) 
’ Beta-blockers 2,116 (96.4%) 2,136 (95.7%) 1,927 (94.3%) 1,376 (93.9%) 408 (93.6%) 151 (94.4%) 754 (94.7%) 8,868 (95.1%) 
 Spironolactone 871 (39.7%) 1,000 (44.8%) 920 (45.0%) 655 (44.7%) 182 (41.7%) 19 (11.9%) 389 (48.9%) 4,036 (43.3%) 
 Potassium 
supplements 
1,154 (52.6%) 1,402 (62.8%) 1,458 (71.4%) 1,096 (74.8%) 314 (72.0%) 58 (36.3%) 541 (68.0%) 6,023 (64.6%) 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Loop diuretics 1,463 (66.7%) 1,744 (78.1%) 1,796 (87.9%) 1,384 (94.4%) 419 (96.1%) 135 (84.4%) 686 (86.2%) 7,627 (81.8%) 
 NSAIDs 520 (23.7%) 503 (22.5%) 482 (23.6%) 374 (25.5%) 114 (26.1%) 24 (15.0%) 209 (26.3%) 2,226 (23.9%) 
 Trimetroprim 23 (1.0%) 50 (2.2%) 66 (3.2%) 71 (4.8%) 23 (5.3%) 2 (1.3%) 28 (3.5%) 263 (2.8%) 
 Macrolides 254 (11.6%) 337 (15.1%) 304 (14.9%) 227 (15.5%) 68 (15.6%) 27 (16.9%) 106 (13.3%) 1,323 (14.2%) 
Hyperkalemia event >5.0 mmol/L         
 Total number of events 495 (22.6%) 719 (32.2%) 842 (41.2%) 659 (45.0%) 203 (46.6%) 101 (63.1%) 257 (32.3%) 3,276 (35.1%) 
 Median years to event 
in pts with event 
1.59 1.10 0.96 0.65 0.52 0.39 3.48 1.02 
 Median no. K+ tests 
before the event 
7 5 5 6 8 5 7 6 
 1-year cumulative 
incidence, % (95% CI) 
8.7 (7.4-9.9) 15.2 (13.5-17.0) 21.3 (19.1-23.6) 27.9 (24.7-31.1) 32.1 (25.7-38.6) 48.1 (33.2-63.0) 3.8 (2.4-5.1) 17.4 (16.5-18.3) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
67.98 (62.12-
74.24) 
111.96 (103.93-
120.46) 
175.34 (163.69-
187.59) 
252.03 (233.15-
272.03) 
320.99 (278.35-
368.31) 
615.89 (501.66-
748.37) 
74.97 (66.09-
84.72) 
129.26 (124.87-
133.76) 
Hyperkalemia event >5.5 mmol/L         
 Total number of events 169 (7.7%) 293 (13.1%) 395 (19.3%) 366 (25.0%) 112 (25.7%) 78 (48.8%) 119 (14.9%) 1,532 (16.4%) 
 Median years to event 
in pts with event 
2.39 1.86 1.53 1.01 0.84 0.54 3.48 1.48 
 Median no. K+ tests 
before the event 
15 11 11 10 13 9 10 11 
 1-year cumulative 
incidence, % (95% CI) 
2.0 (1.4-2.6) 4.4 (3.5-5.3) 7.5 (6.3-8.8) 12.4 (10.5-14.3) 14.0 (10.2-17.8) 33.1 (22.2-44.0) 1.4 (0.6-2.2) 6.5 (5.9-7.0) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
20.74 (17.74-
24.12) 
37.49 (33.32-
42.04) 
65.03 (58.77-
71.77) 
110.77 (99.71-
122.72) 
137.80 (113.46-
165.81) 
356.04 (281.43-
444.35) 
31.65 (26.22-
37.87) 
50.84 (48.33-
53.45) 
Hyperkalemia event >6.0 mmol/L         
 Total number of events 76 (3.5%) 119 (5.3%) 167 (8.2%) 156 (10.6%) 60 (13.8%) 50 (31.3%) 57 (7.2%) 685 (7.3%) 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Median years to event 
in pts with event 
2.57 2.14 1.53 1.26 1.02 0.74 3.79 1.67 
 Median no. K+ tests 
before the event 
18 18 13 13 18 13 13 14 
 1-year cumulative 
incidence, % (95% CI) 
0.5 (0.2-0.9) 1.7 (1.2-2.2) 3.1 (2.4-3.9) 4.6 (3.5-5.8) 6.9 (4.3-9.4) 18.8 (11.3-26.2) 0.8 (0.1-1.4) 2.7 (2.3-3.0) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
9.07 (7.15-
11.35) 
14.39 (11.92-
17.22) 
25.43 (21.72-
29.59) 
43.03 (36.54-
50.34) 
65.02 (49.62-
83.70) 
174.49 (129.51-
230.04) 
14.74 (11.17-
19.10) 
21.46 (19.88-
23.13) 
* Patients categorized according to lowest measured eGFR before or on admission date with heart failure; presence of dialysis overrules any eGFR measurement result. 
† Conditions possibly underlying heart failure; hierarchical categorization: presence before/at first heart failure diagnosis of 1) cardiomyopathy (with or without any of the following 
diagnoses); 2) valvular heart disease (with or without any of the other diagnoses except cardiomyopathy); 3) myocardial infarction (with or without atrial fibrillation); 4) atrial fibrillation 
only; and 5) none of these diagnoses.  
‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 
mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease. 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, 
hyperkalemia; NSAIDs, non-steroidal anti-inflammatory drugs. 
. 
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Table S6. Chronic heart failure: Prevalence of risk factors at time of hyperkalemia/index date 
among heart failure patients and matched comparisons without hyperkalemia 
 
  
Heart failure patients 
with first 
hyperkalemia >5.0 
mmol/L 
Matched heart failure 
comparisons without 
hyperkalemia* 
Matched 
prevalence ratio 
(95% CI) 
 No. of patients  3,276 (100%) 3,094 (100%) 1.00 (1.00-1.00) 
 Females 1,247 (38.1%) 1,154 (37.3%) 1.02 (0.96-1.09) 
 Age, median (quartiles), y 76 (68.1-82.9) 76 (68.6-82.6)  
 K+ tests 6 mo. before 
HK/index date, median 
(quartiles) 
4.0 (1.0-9.0) 1.0 (0.0-3.0)  
 Acute heart failure 
hospitalizations 6 mo. 
before HK/index date 
median (quartiles) 
0.0 (0.0-0.0) 0.0 (0.0-0.0)  
Conditions underlying 
heart failure † 
    
 Cardiomyopathy  507 (15.5%) 439 (14.2%) 1.09 (0.97-1.23) 
 Valvular heart disease  713 (21.8%) 639 (20.7%) 1.05 (0.96-1.16) 
 Myocardial infarction  1,407 (42.9%) 1,257 (40.6%) 1.06 (1.0-1.12) 
 Any ischemic heart 
disease 
2,138 (65.3%) 1,919 (62.0%) 1.05 (1.01-1.09) 
 Atrial fibrillation  1,578 (48.2%) 1,466 (47.4%) 1.02 (0.97-1.07) 
Lowest level of eGFR 
measured before 
hyperkalemia/index date 
    
 No value below 60 
mL/min/1.73m2 
319 (9.7%) 617 (19.9%) 0.49 (0.43-0.55) 
 eGFR 45-59 
mL/min/1.73m2 
613 (18.7%) 798 (25.8%) 0.73 (0.66-0.80) 
 eGFR 30-44 
mL/min/1.73m2 
987 (30.1%) 801 (25.9%) 1.16 (1.08-1.26) 
 eGFR 15-29 
mL/min/1.73m2 
941 (28.7%) 546 (17.6%) 1.63 (1.48-1.79) 
 eGFR<15 mL/min/1.73m2 265 (8.1%) 123 (4.0%) 2.03 (1.65-2.51) 
 Dialysis 122 (3.7%) 25 (0.8%) 4.61 (3.01-7.07) 
 No eGFR measurement 
recorded 
29 (0.9%) 184 (5.9%) 0.15 (0.10-0.22) 
Selected risk factors for 
hyperkalemia 
    
 Diabetes 1,146 (35.0%) 704 (22.8%) 1.54 (1.42-1.67) 
 Chronic kidney disease ‡ 2,414 (73.7%) 1,716 (55.5%) 1.33 (1.28-1.38) 
 Hypertension 3,276 (100%) 3,094 (100%) 1.00 (1.00-1.00) 
Other comorbidities     
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Heart failure patients 
with first 
hyperkalemia >5.0 
mmol/L 
Matched heart failure 
comparisons without 
hyperkalemia* 
Matched 
prevalence ratio 
(95% CI) 
 Peripheral vascular 
disease 
718 (21.9%) 467 (15.1%) 1.45 (1.30-1.61) 
 Cerebrovascular disease 706 (21.6%) 587 (19.0%) 1.14 (1.0-1.25) 
 Chronic pulmonary 
disease 
835 (25.5%) 580 (18.7%) 1.36 (1.2-1.49) 
 Peptic ulcer disease 426 (13.0%) 296 (9.6%) 1.36 (1.2-1.56) 
 Any malignant disease 538 (16.4%) 435 (14.1%) 1.17 (1.04-1.31) 
 Alcoholism-related 
disorders 
364 (11.1%) 230 (7.4%) 1.49 (1.28-1.75) 
 Medical obesity 341 (10.4%) 242 (7.8%) 1.33 (1.14-1.56) 
Use of specific 
hyperkalemia-associated 
medications 
    
 ACEis 2,384 (72.8%) 2,152 (69.6%) 1.05 (1.01-1.08) 
 Ramipril 1,240 (37.9%) 1,064 (34.4%) 1.10 (1.03-1.18) 
 Enalapril 487 (14.9%) 377 (12.2%) 1.22 (1.08-1.38) 
 Other ACEis 729 (22.3%) 728 (23.5%) 0.95 (0.86-1.03) 
 ACEis/diuretics 
combination 
84 (2.6%) 91 (2.9%) 0.87 (0.65-1.17) 
 ARBs 702 (21.4%) 678 (21.9%) 0.98 (0.89-1.07) 
 Losartan 317 (9.7%) 341 (11.0%) 0.88 (0.76-1.01) 
 Candesartan 194 (5.9%) 138 (4.5%) 1.33 (1.07-1.64) 
 Other ARBs 117 (3.6%) 111 (3.6%) 1.00 (0.77-1.28) 
 ARBs/diuretics 
combination 
125 (3.8%) 149 (4.8%) 0.79 (0.63-1.00) 
 Spironolactone 1,728 (52.7%) 1,168 (37.8%) 1.40 (1.32-1.48) 
 Potassium supplements 1,875 (57.2%) 1,618 (52.3%) 1.09 (1.05-1.14) 
 Loop diuretics 2,738 (83.6%) 2,270 (73.4%) 1.14 (1.11-1.17) 
 NSAIDs 709 (21.6%) 610 (19.7%) 1.10 (1.00-1.21) 
 Trimetroprim 131 (4.0%) 84 (2.7%) 1.47 (1.12-1.93) 
 Macrolides 473 (14.4%) 320 (10.3%) 1.40 (1.22-1.59) 
 
* Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the 
hyperkalemia/index date 
† As present at the time of heart failure diagnosis.  
‡ Manifest CKD was defined on the date of the second of two measurements more than 90 days apart of a creatinine value 
corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease, see text 
and Supplementary material with codes 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; 
eGFR, estimated Glomerular Filtration Rate; NSAIDs, non-steroidal anti-inflammatory drugs; PR, prevalence ratio
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Table S7. Chronic heart failure. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully matched 
comparisons without HK.  
 
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure 
comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted 
Hazard Ratio 
 (95% CI) 
Any hospital outpatient contact  2,246 (3,091.43) 1,448 (1,312.78) 1.98 (1.85-2.13) 1.50 (1.37-1.64) 
Any acute hospitalization  1,967 (2,499.73) 678 (506.10) 3.72 (3.39-4.08) 2.10 (1.87-2.37) 
Any non-acute hospitalization  745 (659.76) 298 (208.70) 2.74 (2.38-3.16) 1.98 (1.67-2.35) 
Any cardiac diagnosis 1,498 (1,604.57) 449 (320.60) 3.85 (3.45-4.31) 2.21 (1.92-2.55) 
Ventricular arrhythmia 110 (83.26) 25 (16.67) 4.06 (2.58-6.41) 2.07 (1.18-3.80) 
Cardiac arrest 32 (23.68) 5 (3.32) 7.29 (2.70-19.70) 7.23 (0.00-378E6) 
Dialysis procedure 94 (70.86) 11 (7.32) 3.44 (1.53-7.78) 2.29 (1.24-4.27) 
Ventilator treatment 174 (131.55) 26 (17.29) 7.26 (4.73-11.16) 2.62 (0.94-6.28) 
ICU admission 413 (326.52) 58 (38.72) 8.01 (6.02-10.66) 4.85 (3.25-7.57) 
Heart failure re-admission 761 (661.07) 170 (115.99) 4.27 (3.58-5.08) 2.10 (1.72-2.56) 
ACEi prescription  1,781 (2,582.50) 1,819 (2,289.60) 1.02 (0.95-1.09) 0.96 (0.92-1.00) 
ARB prescription 506 (430.54) 599 (465.76) 0.93 (0.82-1.06) 0.96 (0.90-1.03) 
Spironolactone prescription 1,122 (1,155.93) 896 (751.44) 1.01 (0.92-1.10) 0.86 (0.81-0.92) 
Potassium supplement prescription  1,128 (1,137.80) 1,287 (1,238.69) 0.84 (0.77-0.91) 0.80 (0.75-0.85) 
Death 773 (570.99) 162 (107.61) 4.76 (3.98-5.69) - 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, see text. 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment regimen, number of acute heart failure hospitalizations 6 months before 
the HK/index date, eGFR category, Charlson Comorbidity Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium supplements 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios observed 6 months after vs. 6 months before the HK/index date,see text 
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Table S8. Restricted analysis to patients with 5 K+ tests: Baseline characteristics among patients with first hospital diagnosed heart 
failure, stratified by eGFR category and subsequent incidence of hyperkalemia. 
  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Number of HF patients 
(row %) 
5,824 (28.5%) 5,401 (26.4%) 4,568 (22.3%) 3,008 (14.7%) 961 (4.7%) 215 (1.1%) 479 (2.3%) 20,456 (100%) 
 Female 1,931 (33.2%) 2,513 (46.5%) 2,513 (55.0%) 1,628 (54.1%) 505 (52.5%) 67 (31.2%) 202 (42.2%) 9,359 (45.8%) 
 Median age (quartiles) 70 (60.4-78.7) 78 (69.5-83.9) 81 (74.2-86.6) 82 (75.6-87.2) 81 (72.6-85.8) 69 (60.2-78.7) 72 (62.0-79.1) 77 (68.1-84.3) 
 Echocardiography 
performed before / at 
first HF admission  
4,030 (69.2%) 3,509 (65.0%) 2,835 (62.1%) 1,936 (64.4%) 636 (66.2%) 176 (81.9%) 285 (59.5%) 13,407 (65.5%) 
 Heart failure as primary 
diagnosis 
2,345 (40.3%) 2,083 (38.6%) 1,687 (36.9%) 1,022 (34.0%) 321 (33.4%) 93 (43.3%) 188 (39.2%) 7,739 (37.8%) 
Conditions underlying heart failure †         
 Cardiomyopathy  393 (6.7%) 250 (4.6%) 161 (3.5%) 110 (3.7%) 21 (2.2%) 9 (4.2%) 20 (4.2%) 964 (4.7%) 
 Valvular heart disease  676 (11.6%) 766 (14.2%) 766 (16.8%) 523 (17.4%) 167 (17.4%) 40 (18.6%) 94 (19.6%) 3,032 (14.8%) 
 Myocardial infarction  1,083 (18.6%) 1,141 (21.1%) 1,106 (24.2%) 817 (27.2%) 260 (27.1%) 76 (35.3%) 92 (19.2%) 4,575 (22.4%) 
 Any ischemic heart 
disease 
2,062 (35.4%) 2,209 (40.9%) 2,010 (44.0%) 1,445 (48.0%) 437 (45.5%) 119 (55.3%) 202 (42.2%) 8,484 (41.5%) 
 Atrial fibrillation  1,902 (32.7%) 2,103 (38.9%) 1,817 (39.8%) 1,171 (38.9%) 349 (36.3%) 57 (26.5%) 124 (25.9%) 7,523 (36.8%) 
          
Other 
comorbidities 
         
 Diabetes 962 (16.5%) 943 (17.5%) 1,005 (22.0%) 857 (28.5%) 319 (33.2%) 82 (38.1%) 83 (17.3%) 4,251 (20.8%) 
 Chronic kidney 
disease‡ 
33 (0.6%) 2,803 (51.9%) 3,659 (80.1%) 2,653 (88.2%) 890 (92.6%) 215 (100%) 18 (3.8%) 10,271 (50.2%) 
 Hypertension 2,916 (50.1%) 3,432 (63.5%) 3,367 (73.7%) 2,439 (81.1%) 800 (83.2%) 200 (93.0%) 214 (44.7%) 13,368 (65.4%) 
 Peripheral vascular 
disease 
436 (7.5%) 586 (10.8%) 590 (12.9%) 547 (18.2%) 222 (23.1%) 70 (32.6%) 46 (9.6%) 2,497 (12.2%) 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Cerebrovascular 
disease 
691 (11.9%) 870 (16.1%) 946 (20.7%) 707 (23.5%) 243 (25.3%) 45 (20.9%) 41 (8.6%) 3,543 (17.3%) 
 Chronic pulmonary 
disease 
999 (17.2%) 1,005 (18.6%) 915 (20.0%) 615 (20.4%) 178 (18.5%) 42 (19.5%) 59 (12.3%) 3,813 (18.6%) 
 Peptic ulcer disease 385 (6.6%) 452 (8.4%) 498 (10.9%) 402 (13.4%) 151 (15.7%) 41 (19.1%) 33 (6.9%) 1,962 (9.6%) 
 Any malignant disease 667 (11.5%) 811 (15.0%) 804 (17.6%) 596 (19.8%) 190 (19.8%) 44 (20.5%) 37 (7.7%) 3,149 (15.4%) 
 Alcoholism-related 
disorders 
623 (10.7%) 343 (6.4%) 300 (6.6%) 267 (8.9%) 109 (11.3%) 34 (15.8%) 28 (5.8%) 1,704 (8.3%) 
 Medical obesity 457 (7.8%) 351 (6.5%) 313 (6.9%) 267 (8.9%) 109 (11.3%) 16 (7.4%) 26 (5.4%) 1,539 (7.5%) 
Drug treatment, before first admission         
 ACEis overall 1,125 (19.3%) 1,260 (23.3%) 1,235 (27.0%) 933 (31.0%) 304 (31.6%) 71 (33.0%) 102 (21.3%) 5,030 (24.6%) 
 Ramipril 434 (7.5%) 498 (9.2%) 457 (10.0%) 361 (12.0%) 109 (11.3%) 34 (15.8%) 21 (4.4%) 1,914 (9.4%) 
 Enalapril 332 (5.7%) 373 (6.9%) 373 (8.2%) 277 (9.2%) 95 (9.9%) 24 (11.2%) 24 (5.0%) 1,498 (7.3%) 
 Other ACEis 284 (4.9%) 306 (5.7%) 329 (7.2%) 247 (8.2%) 73 (7.6%) 12 (5.6%) 53 (11.1%) 1,304 (6.4%) 
 ACEis/diuretics 
combination 
132 (2.3%) 146 (2.7%) 141 (3.1%) 105 (3.5%) 45 (4.7%) 4 (1.9%) 8 (1.7%) 581 (2.8%) 
 ARBs overall 485 (8.3%) 579 (10.7%) 614 (13.4%) 509 (16.9%) 195 (20.3%) 48 (22.3%) 35 (7.3%) 2,465 (12.1%) 
 Losartan 204 (3.5%) 235 (4.4%) 251 (5.5%) 205 (6.8%) 86 (8.9%) 17 (7.9%) 15 (3.1%) 1,013 (5.0%) 
 Candesartan 85 (1.5%) 104 (1.9%) 99 (2.2%) 79 (2.6%) 37 (3.9%) 22 (10.2%) 5 (1.0%) 431 (2.1%) 
 Other ARBs 72 (1.2%) 91 (1.7%) 96 (2.1%) 73 (2.4%) 26 (2.7%) 9 (4.2%) 10 (2.1%) 377 (1.8%) 
 ARBs/diuretics 
combination 
173 (3.0%) 192 (3.6%) 205 (4.5%) 193 (6.4%) 59 (6.1%) 5 (2.3%) 6 (1.3%) 833 (4.1%) 
’ Beta-blockers 1,429 (24.5%) 1,626 (30.1%) 1,570 (34.4%) 1,241 (41.3%) 418 (43.5%) 132 (61.4%) 122 (25.5%) 6,538 (32.0%) 
 Spironolactone 361 (6.2%) 455 (8.4%) 599 (13.1%) 510 (17.0%) 167 (17.4%) 4 (1.9%) 49 (10.2%) 2,145 (10.5%) 
 Potassium 
supplements 
1,064 (18.3%) 1,452 (26.9%) 1,583 (34.7%) 1,259 (41.9%) 378 (39.3%) 49 (22.8%) 143 (29.9%) 5,928 (29.0%) 
 Loop diuretics 1,380 (23.7%) 1,815 (33.6%) 2,002 (43.8%) 1,794 (59.6%) 622 (64.7%) 142 (66.0%) 190 (39.7%) 7,945 (38.8%) 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 NSAIDs 1,276 (21.9%) 1,169 (21.6%) 996 (21.8%) 734 (24.4%) 237 (24.7%) 19 (8.8%) 122 (25.5%) 4,553 (22.3%) 
 Trimetroprim 62 (1.1%) 114 (2.1%) 136 (3.0%) 129 (4.3%) 49 (5.1%) 3 (1.4%) 5 (1.0%) 498 (2.4%) 
 Macrolides 723 (12.4%) 641 (11.9%) 507 (11.1%) 382 (12.7%) 119 (12.4%) 30 (14.0%) 57 (11.9%) 2,459 (12.0%) 
Hyperkalemia event >5.0 mmol/L         
 Total number of events 785 (13.5%) 956 (17.7%) 1,080 (23.6%) 950 (31.6%) 338 (35.2%) 91 (42.3%) 84 (17.5%) 4,284 (20.9%) 
 Median years to event 
in pts with event 
0.11 0.10 0.09 0.04 0.03 0.12 0.29 0.08 
 Median no. K+ tests 
before the event 
2 2 2 1 1 1 1 2 
 1-year cumulative 
incidence, % (95% CI) 
13.5 (12.5-14.5) 17.7 (16.5-18.9) 23.6 (22.0-25.3) 31.6 (29.2-34.0) 35.2 (30.5-39.8) 42.3 (30.9-53.8) 17.5 (13.4-21.7) 20.9 (20.2-21.6) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
40.48 (37.70-
43.41) 
61.94 (58.07-
65.99) 
110.99 (104.47-
117.81) 
213.88 (200.50-
227.93) 
295.93 (265.22-
329.22) 
414.30 (333.57-
508.67) 
38.92 (31.05-
48.19) 
81.57 (79.14-
84.05) 
Hyperkalemia event >5.5 mmol/L         
 Total number of events 192 (3.3%) 272 (5.0%) 396 (8.7%) 400 (13.3%) 151 (15.7%) 52 (24.2%) 33 (6.9%) 1,496 (7.3%) 
 Median years to event 
in pts with event 
0.11 0.10 0.10 0.04 0.02 0.22 0.30 0.08 
 Median no. K+ tests 
before the event 
2 2 2 1 1 2 1 2 
 1-year cumulative 
incidence, % (95% CI) 
3.3 (2.8-3.8) 5.0 (4.4-5.7) 8.7 (7.8-9.6) 13.3 (11.9-14.7) 15.7 (13.0-18.4) 24.2 (16.6-31.7) 6.9 (4.5-9.3) 7.3 (6.9-7.7) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
9.01 (7.78-
10.37) 
15.62 (13.82-
17.59) 
35.33 (31.94-
38.99) 
73.89 (66.83-
81.50) 
105.90 (89.68-
124.20) 
179.54 (134.09-
235.44) 
13.96 (9.61-
19.60) 
25.17 (23.91-
26.48) 
Hyperkalemia event >6.0 mmol/L         
 Total number of events 58 (1.0%) 99 (1.8%) 142 (3.1%) 167 (5.6%) 72 (7.5%) 20 (9.3%) 9 (1.9%) 567 (2.8%) 
 Median years to event 
in pts with event 
0.12 0.12 0.10 0.06 0.01 0.25 0.17 0.09 
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  eGFR category (mL/min/1.73m2)*  
  eGFR>= 60 eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
 Median no. K+ tests 
before the event 
2 3 2 2 1 2 1 2 
 1-year cumulative 
incidence, % (95% CI) 
1.0 (0.7-1.3) 1.8 (1.5-2.2) 3.1 (2.6-3.6) 5.6 (4.7-6.4) 7.5 (5.7-9.3) 9.3 (5.0-13.6) 1.9 (0.6-3.1) 2.8 (2.5-3.0) 
 Incidence rate of HK / 
1,000 person-years 
(95% CI) 
2.69 (2.04-3.47) 5.55 (4.51-6.76) 12.15 (10.23-
14.32) 
29.01 (24.77-
33.75) 
47.67 (37.30-
60.04) 
56.53 (34.53-
87.31) 
3.72 (1.70-7.07) 9.27 (8.52-
10.06) 
* Patients categorized according to lowest measured eGFR before or on admission date with heart failure; presence of dialysis overrules any eGFR measurement result. 
† Conditions possibly underlying heart failure; hierarchical categorization: presence before/at first heart failure diagnosis of 1) cardiomyopathy (with or without any of the following 
diagnoses); 2) valvular heart disease (with or without any of the other diagnoses except cardiomyopathy); 3) myocardial infarction (with or without atrial fibrillation); 4) atrial fibrillation 
only; and 5) none of these diagnoses.  
‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 
mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease. 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, 
hyperkalemia; NSAIDs, non-steroidal anti-inflammatory drugs. 
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Table S9. Restricted analysis to patients with 5 K+ tests: Prevalence of risk factors at time of 
hyperkalemia/index date among heart failure patients and matched comparisons without 
hyperkalemia 
 
  
Heart failure patients 
with first 
hyperkalemia >5.0 
mmol/L 
Matched heart 
failure comparisons 
without 
hyperkalemia* 
Matched 
prevalence ratio 
(95% CI) 
 No. of patients  4,284 (100%) 4,204 (100%) 1.00 (1.00-1.00) 
 Females 1,995 (46.6%) 1,964 (46.7%) 1.00 (0.95-1.04) 
 Age, median (quartiles), y 78.7 (70.2-85.2) 78.9 (70.8-85.2)  
 K+ tests 6 mo. before 
HK/index date, median 
(quartiles) 
1.0 (0.0-3.0) 1.0 (0.0-3.0)  
 Acute heart failure 
hospitalizations 6 mo. 
before HK/index date 
median (quartiles) 
0.0 (0.0-1.0) 0.0 (0.0-1.0)  
Conditions underlying 
heart failure † 
    
 Cardiomyopathy  261 (6.1%) 247 (5.9%) 1.04 (0.88-1.23) 
 Valvular heart disease  720 (16.8%) 628 (14.9%) 1.13 (1.02-1.24) 
 Myocardial infarction  1,159 (27.1%) 1,141 (27.1%) 1.00 (0.9-1.07) 
 Any ischemic heart disease 1,877 (43.8%) 1,798 (42.8%) 1.02 (0.98-1.08) 
 Atrial fibrillation  1,534 (35.8%) 1,623 (38.6%) 0.93 (0.88-0.98) 
     
Lowest level of eGFR 
measured before 
hyperkalemia/index date 
    
 No value below 60 
mL/min/1.73m2 
502 (11.7%) 854 (20.3%) 0.58 (0.52-0.64) 
 eGFR 45-59 
mL/min/1.73m2 
762 (17.8%) 1,124 (26.7%) 0.67 (0.61-0.72) 
 eGFR 30-44 
mL/min/1.73m2 
1,154 (26.9%) 1,112 (26.5%) 1.02 (0.95-1.09) 
 eGFR 15-29 
mL/min/1.73m2 
1,232 (28.8%) 766 (18.2%) 1.58 (1.46-1.71) 
 eGFR<15 mL/min/1.73m2 463 (10.8%) 198 (4.7%) 2.29 (1.95-2.70) 
 Dialysis 117 (2.7%) 43 (1.0%) 2.67 (1.89-3.78) 
 No eGFR measurement 
recorded 
54 (1.3%) 107 (2.5%) 0.50 (0.36-0.69) 
Selected risk factors for 
hyperkalemia 
    
 Diabetes 1,194 (27.9%) 850 (20.2%) 1.38 (1.28-1.49) 
 Chronic kidney disease ‡ 2,815 (65.7%) 2,247 (53.4%) 1.23 (1.19-1.27) 
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Heart failure patients 
with first 
hyperkalemia >5.0 
mmol/L 
Matched heart 
failure comparisons 
without 
hyperkalemia* 
Matched 
prevalence ratio 
(95% CI) 
 Hypertension 3,436 (80.2%) 3,264 (77.6%) 1.03 (1.01-1.06) 
Other comorbidities     
 Peripheral vascular disease 680 (15.9%) 579 (13.8%) 1.15 (1.0-1.28) 
 Cerebrovascular disease 803 (18.7%) 814 (19.4%) 0.97 (0.9-1.06) 
 Chronic pulmonary disease 1,051 (24.5%) 906 (21.6%) 1.14 (1.1-1.23) 
 Peptic ulcer disease 509 (11.9%) 448 (10.7%) 1.11 (1.0-1.26) 
 Any malignant disease 704 (16.4%) 681 (16.2%) 1.01 (0.92-1.12) 
 Alcoholism-related 
disorders 
398 (9.3%) 330 (7.8%) 1.18 (1.03-1.36) 
 Medical obesity 330 (7.7%) 260 (6.2%) 1.25 (1.06-1.46) 
Use of specific 
hyperkalemia-associated 
medications 
    
 ACEis overall 1,829 (42.7%) 1,641 (39.0%) 1.09 (1.04-1.15) 
 Ramipril 1,240 (37.9%) 1,064 (34.4%) 1.11 (1.02-1.21) 
 Enalapril 433 (10.1%) 358 (8.5%) 1.19 (1.04-1.36) 
 Other ACEis 469 (10.9%) 477 (11.3%) 0.96 (0.86-1.09) 
 ACEis/diuretics combination 137 (3.2%) 104 (2.5%) 1.29 (1.01-1.66) 
 ARBs overall 637 (14.9%) 549 (13.1%) 1.14 (1.02-1.27) 
 Losartan 246 (5.7%) 235 (5.6%) 1.03 (0.86-1.22) 
 Candesartan 170 (4.0%) 107 (2.5%) 1.56 (1.23-1.98) 
 Other ARBs 94 (2.2%) 92 (2.2%) 1.00 (0.75-1.33) 
 ARBs/diuretics combination 173 (4.0%) 174 (4.1%) 0.98 (0.79-1.20) 
 Spironolactone 1,289 (30.1%) 856 (20.4%) 1.48 (1.37-1.59) 
 Potassium supplements 1,969 (46.0%) 2,021 (48.1%) 0.96 (0.91-1.00) 
 Loop diuretics 2,628 (61.3%) 2,464 (58.6%) 1.05 (1.01-1.08) 
 NSAIDs 904 (21.1%) 929 (22.1%) 0.95 (0.88-1.04) 
 Trimetroprim 130 (3.0%) 129 (3.1%) 0.99 (0.78-1.26) 
 Macrolides 539 (12.6%) 456 (10.8%) 1.16 (1.03-1.30) 
 
* Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the 
hyperkalemia/index date 
† As present at the time of heart failure diagnosis.  
‡ Manifest CKD was defined on the date of the second of two measurements more than 90 days apart of a creatinine value 
corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of chronic kidney disease, see text 
and Supplementary material with codes 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; 
eGFR, estimated Glomerular Filtration Rate; NSAIDs, non-steroidal anti-inflammatory drugs; PR, prevalence ratio  
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Table S10. Restricted analysis to patients with 5 K+ tests: Hazard ratios for clinical outcomes 
6 months after hyperkalemia (HK) versus fully matched comparisons without HK.  
 
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure 
comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  2,604 (3,326.63) 2,571 (2,293.14) 1.35 (1.27-1.42) 1.35 (1.26-1.45) 
Any acute hospitalization  3,270 (5,344.31) 2,386 (2,123.88) 1.99 (1.89-2.11) 2.10 (1.97-2.24) 
Any non-acute hospitalization  914 (787.09) 930 (582.76) 1.33 (1.20-1.46) 1.29 (1.17-1.46) 
Any cardiac diagnosis 2,823 (3,861.86) 2,025 (1,668.35) 1.88 (1.77-1.99) 2.07 (1.92-2.21) 
Ventricular arrhythmia 148 (106.70) 95 (51.39) 1.99 (1.52-2.59) 2.11 (1.55-3.00) 
Cardiac arrest 59 (41.51) 27 (14.40) 2.95 (1.84-4.74) 3.43 (1.32-10.18) 
Dialysis procedure 105 (75.05) 28 (14.94) 2.76 (1.78-4.26) 1.67 (1.11-2.39) 
Ventilator treatment 367 (269.33) 105 (56.57) 4.53 (3.63-5.66) 3.93 (2.81-5.81) 
ICU admission 620 (478.84) 265 (146.38) 3.08 (2.65-3.57) 3.18 (2.58-3.97) 
Heart failure re-admission 2,270 (2,567.94) 1,612 (1,219.48) 1.77 (1.65-1.89) 2.01 (1.87-2.15) 
ACEi prescription  1,351 (1,434.42) 1,682 (1,371.36) 0.94 (0.87-1.01) 0.86 (0.81-0.92) 
ARB prescription 397 (307.06) 453 (262.90) 1.06 (0.92-1.22) 0.99 (0.88-1.10) 
Spironolactone prescription 920 (817.07) 999 (654.70) 0.93 (0.85-1.02) 0.72 (0.66-0.78) 
Potassium supplement prescription  1,080 (997.58) 1,956 (1,655.61) 0.65 (0.60-0.70) 0.63 (0.58-0.67) 
Death 1,764 (1,235.55) 717 (381.14) 2.95 (2.70-3.23) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
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Table S11. Primary heart failure diagnosis: Baseline characteristics among patients with a first primary hospital diagnosis of heart 
failure, stratified by eGFR category and subsequent incidence of hyperkalemia 
 eGFR category (mL/min/1.73m2)*  
 eGFR >= 60  eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
Number of HF patients (row %) 2,977 (25.0%) 2,586 (21.7%) 2,109 (17.7%) 1,277 (10.7%) 412 (3,5%) 124 (1.0%) 2,423 (20.3%) 11,908 (100%) 
Females 995 (33.4%) 1,160 (44.9%) 1,141 (54.1%) 683 (53.5%) 211 (51.2%) 39 (31.5%) 1,154 (47.6%) 5,383 (45.2%) 
Median age in years (quartiles) 70 (59.6-78.7) 78 (69.3-83.9) 82 (74.7-87.3) 83 (76.2-87.9) 81 (72.7-86.4) 68 (60.5-78.4) 79 (70.9-85.5) 78 (68.3-84.9) 
Echocardiography performed before / at 
first HF admission  
2,107 (70.8%) 1,712 (66.2%) 1,313 (62.3%) 784 (61.4%) 267 (64.8%) 86 (69.4%) 1,008 (41.6%) 7,277 (61.1%) 
Heart failure as primary diagnosis 2,977 (100%) 2,586 (100%) 2,109 (100%) 1,277 (100%) 412 (100%) 124 (100%) 2,423 (100%) 11,908 (100%) 
Conditions underlying HF         
Cardiomyopathy 258 (8.7%) 172 (6.7%) 94 (4.5%) 53 (4.2%) 8 (1.9%) 5 (4.0%) 82 (3.4%) 672 (5.6%) 
Valvular heart disease  333 (11.2%) 355 (13.7%) 345 (16.4%) 233 (18.2%) 70 (17.0%) 21 (16.9%) 247 (10.2%) 1,604 (13.5%) 
Myocardial infarction 466 (15.7%) 525 (20.3%) 474 (22.5%) 351 (27.5%) 116 (28.2%) 41 (33.1%) 362 (14.9%) 2,335 (19.6%) 
Ischemic heart disease 858 (28.8%) 897 (34.7%) 809 (38.4%) 566 (44.3%) 181 (43.9%) 60 (48.4%) 692 (28.6%) 4,063 (34.1%) 
Atrial fibrillation 864 (29.0%) 933 (36.1%) 822 (39.0%) 493 (38.6%) 132 (32.0%) 25 (20.2%) 738 (30.5%) 4,007 (33.6%) 
         
Other comorbidities         
Diabetes 498 (16.7%) 442 (17.1%) 439 (20.8%) 351 (27.5%) 125 (30.3%) 48 (38.7%) 407 (16.8%) 2,310 (19.4%) 
Chronic kidney disease ‡ 21 (0.7%) 1,339 (51.8%) 1,663 (78.9%) 1,130 (88.5%) 379 (92.0%) 124 (100%) 92 (3.8%) 4,748 (39.9%) 
Hypertension 1,490 (50.1%) 1,671 (64.6%) 1,539 (73.0%) 1,017 (79.6%) 337 (81.8%) 113 (91.1%) 1,132 (46.7%) 7,299 (61.3%) 
Peripheral vascular disease 186 (6.2%) 263 (10.2%) 261 (12.4%) 220 (17.2%) 96 (23.3%) 46 (37.1%) 258 (10.6%) 1,330 (11.2%) 
Cerebrovascular disease 354 (11.9%) 409 (15.8%) 395 (18.7%) 278 (21.8%) 105 (25.5%) 31 (25.0%) 370 (15.3%) 1,942 (16.3%) 
Chronic pulmonary disease 387 (13.0%) 416 (16.1%) 327 (15.5%) 215 (16.8%) 54 (13.1%) 19 (15.3%) 345 (14.2%) 1,763 (14.8%) 
Peptic ulcer disease 183 (6.1%) 214 (8.3%) 227 (10.8%) 175 (13.7%) 50 (12.1%) 23 (18.5%) 207 (8.5%) 1,079 (9.1%) 
Any malignant disease 366 (12.3%) 375 (14.5%) 370 (17.5%) 261 (20.4%) 83 (20.1%) 25 (20.2%) 260 (10.7%) 1,740 (14.6%) 
Alcoholism-related disorders 283 (9.5%) 158 (6.1%) 137 (6.5%) 102 (8.0%) 37 (9.0%) 10 (8.1%) 138 (5.7%) 865 (7.3%) 
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 eGFR category (mL/min/1.73m2)*  
 eGFR >= 60  eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
Medical obesity 249 (8.4%) 165 (6.4%) 145 (6.9%) 92 (7.2%) 37 (9.0%) 9 (7.3%) 129 (5.3%) 826 (6.9%) 
Drug treatment before first HF 
diagnosis 
        
ACEis overall 609 (20.5%) 671 (25.9%) 559 (26.5%) 380 (29.8%) 127 (30.8%) 42 (33.9%) 452 (18.7%) 2,840 (23.8%) 
Ramipril 263 (8.8%) 276 (10.7%) 220 (10.4%) 160 (12.5%) 51 (12.4%) 18 (14.5%) 84 (3.5%) 1,072 (9.0%) 
Enalapril 156 (5.2%) 179 (6.9%) 155 (7.3%) 112 (8.8%) 39 (9.5%) 16 (12.9%) 129 (5.3%) 786 (6.6%) 
Other ACEis 156 (5.2%) 171 (6.6%) 151 (7.2%) 95 (7.4%) 30 (7.3%) 8 (6.5%) 234 (9.7%) 845 (7.1%) 
ACEis/diuretics combination 61 (2.0%) 72 (2.8%) 61 (2.9%) 38 (3.0%) 16 (3.9%) 2 (1.6%) 26 (1.1%) 276 (2.3%) 
ARBs overall 228 (7.7%) 270 (10.4%) 289 (13.7%) 204 (16.0%) 72 (17.5%) 32 (25.8%) 152 (6.3%) 1,247 (10.5%) 
Losartan 93 (3.1%) 111 (4.3%) 120 (5.7%) 89 (7.0%) 33 (8.0%) 15 (12.1%) 75 (3.1%) 536 (4.5%) 
Candesartan 39 (1.3%) 52 (2.0%) 47 (2.2%) 32 (2.5%) 14 (3.4%) 11 (8.9%) 25 (1.0%) 220 (1.8%) 
Other ARBs 28 (0.9%) 46 (1.8%) 51 (2.4%) 24 (1.9%) 10 (2.4%) 6 (4.8%) 29 (1.2%) 194 (1.6%) 
ARBs/diuretics combination 86 (2.9%) 81 (3.1%) 93 (4.4%) 73 (5.7%) 18 (4.4%) 3 (2.4%) 40 (1.7%) 394 (3.3%) 
Beta blockers 763 (25.6%) 797 (30.8%) 731 (34.7%) 504 (39.5%) 166 (40.3%) 76 (61.3%) 565 (23.3%) 3,602 (30.2%) 
Spironolactone  193 (6.5%) 220 (8.5%) 269 (12.8%) 207 (16.2%) 70 (17.0%) 2 (1.6%) 326 (13.5%) 1,287 (10.8%) 
Potassium supplements 563 (18.9%) 691 (26.7%) 761 (36.1%) 528 (41.3%) 163 (39.6%) 24 (19.4%) 864 (35.7%) 3,594 (30.2%) 
Loop diuretics  757 (25.4%) 917 (35.5%) 966 (45.8%) 755 (59.1%) 260 (63.1%) 74 (59.7%) 1,066 (44.0%) 4,795 (40.3%) 
NSAIDs 644 (21.6%) 534 (20.6%) 447 (21.2%) 305 (23.9%) 100 (24.3%) 11 (8.9%) 569 (23.5%) 2,610 (21.9%) 
Trimetoprim 32 (1.1%) 51 (2.0%) 60 (2.8%) 67 (5.2%) 24 (5.8%) 2 (1.6%) 75 (3.1%) 311 (2.6%) 
Macrolides   369 (12.4%) 299 (11.6%) 208 (9.9%) 160 (12.5%) 48 (11.7%) 10 (8.1%) 309 (12.8%) 1,403 (11.8%) 
HK event >5.0 mmol/L         
Total N (%) with a first HK event 1,164 (39.1%) 1,168 (45.2%) 1,104 (52.3%) 715 (56.0%) 220 (53.4%) 78 (62.9%) 486 (20.1%) 4,935 (41.4%) 
Median years to event in pts with event 0.52 0.44 0.19 0.10 0.11 0.15 3.81 0.37 
Median no. K+ tests before first event 9 8 7 6 6 7 8 8 
1-year cumulative incidence, % (95% CI) 23.4 (21.4-25.4) 29.2 (26.7-31.6) 37.9 (34.6-41.3) 45.5 (40.5-50.5) 45.9 (37.0-54.8) 51.6 (33.4-69.8) 3.1 (2.4-3.8) 26.5 (25.5-27.6) 
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 eGFR category (mL/min/1.73m2)*  
 eGFR >= 60  eGFR 45-59  eGFR 30-44  eGFR 15-29  eGFR<15  Dialysis 
No eGFR 
recorded Total 
Incidence rate per 1,000 person-years 144.6 220.1 380.3 639.5 725.4 1,151.7 63.3  194.1 
HK event >5.5 mmol/L         
Total N (%) with a first HK event 477 (16.0%) 587 (22.7%) 611 (29.0%) 441 (34.5%) 151 (36.7%) 61 (49.2%) 232 (9.6%) 2,560 (21.5%) 
Median years to event in pts with event 1.10 0.82 0.47 0.19 0.09 0.22 4.28 0.64 
Median no. K+ tests before first event 14 12 10 8 7 10 12 11 
1-year cumulative incidence, % (95% CI) 7.8 (6.8-8.9) 12.0 (10.6-13.4) 17.8 (15.8-19.8) 25.2 (22.0-28.4) 28.6 (22.5-34.8) 34.7 (21.9-47.5) 1.2 (0.8-1.6) 12.0 (11.4-12.7) 
Incidence rate per 1,000 person-years 46.4 80.0 150.0  269.7 338.8 635.5 27.7 79.4 
HK event >6.0 mmol/L         
Total N (%) with a first HK event 204 (6.9%) 257 (9.9%) 302 (14.3%) 235 (18.4%) 77 (18.7%) 37 (29.8%) 109 (4.5%) 1,221 (10.3%) 
Median years to event in pts with event 1.61 1.34 0.76 0.26 0.16 0.38 4.15 0.92 
Median no. K+ tests before first event 18 17 13 9 8 10 14 13 
1-year cumulative incidence, % (95% CI) 2.9 (2.2-3.5) 4.4 (3.5-5.2) 7.7 (6.5-8.9) 13.3 (11.2-15.5) 14.6 (10.6-18.5) 21.0 (11.9-30.0) 0.4 (0.2-0.7) 5.3 (4.8-5.7) 
Incidence rate per 1,000 person-years 18.7 31.7 64.1 123.1 138.2 253.4 12.7 34.9 
         
* Patients categorized according to lowest measured eGFR before or on admission date with heart failure; presence of dialysis overrules any eGFR measurement result. 
† Conditions possibly underlying heart failure; hierarchical categorization: presence before/at first heart failure diagnosis of 1) cardiomyopathy (with or without any of the following 
diagnoses); 2) valvular heart disease (with or without any of the other diagnoses except cardiomyopathy); 3) myocardial infarction (with or without atrial fibrillation); 4) atrial fibrillation 
only; and 5) none of these diagnoses.  
‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart of a creatinine value corresponding to an eGFR below 60 
mL/min/1.73m2, or on the first date of a hospital diagnosis. 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, confidence interval; eGFR, estimated Glomerular Filtration Rate; HK,  
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on May 7, 2019
  
 
 
Table S12. Primary heart failure diagnosis: Prevalence of risk factors at time of 
hyperkalemia/index date among heart failure patients and matched comparisons without 
hyperkalemia 
 
 
Heart failure 
patients with 
first HK >5.0 
mmol/L 
Matched* 
heart failure 
comparisons 
without HK 
Matched 
Prevalence 
Ratio 
(95% CI) 
No. of patients  4,935 (100%) 4,679 (100%)  
Females 2,164 (43.9%) 2,046 (43.7%)  
Age, median (quartiles), y 78.4 (69.7-85.1) 78.6 (70.5-84.9)  
K+ tests 6 mo. before HK/index date, median 
(quartiles) 
5.0 (2.0-10.0) 2.0 (0.0-5.0)  
Acute heart failure hospitalizations 6 mo. before 
HK/index date median (quartiles) 
0.0 (0.0-1.0) 0.0 (0.0-1.0)  
Conditions underlying heart failure †    
Cardiomyopathy 500 (10.1%) 434 (9.3%) 1.09 (0.97-1.23) 
Valvular heart disease 888 (18.0%) 702 (15.0%) 1.20 (1.10-1.31) 
Myocardial infarction 1,184 (24.0%) 995 (21.3%) 1.13 (1.0-1.22) 
Any ischemic heart disease 2,120 (43.0%) 1,836 (39.2%) 1.09 (1.04-1.15) 
Atrial fibrillation 1,889 (38.3%) 1,712 (36.6%) 1.05 (0.99-1.10) 
Lowest eGFR measured before HK/index date    
No values below 60 mL/min/1.73m2 661 (13.4%) 1,020 (21.8%) 0.61 (0.56-0.67) 
eGFR 45-59 mL/min/1.73m2 1,011 (20.5%) 1,157 (24.7%) 0.83 (0.77-0.89) 
eGFR 30-44 mL/min/1.73m2 1,501 (30.4%) 943 (20.2%) 1.51 (1.41-1.62) 
eGFR 15-29 mL/min/1.73m2 1,242 (25.2%) 537 (11.5%) 2.19 (2.00-2.41) 
eGFR<15 mL/min/1.73m2 312 (6.3%) 110 (2.4%) 2.69 (2.17-3.33) 
Dialysis 112 (2.3%) 36 (0.8%) 2.95 (2.03-4.28) 
No eGFR measurement recorded 96 (1.9%) 876 (18.7%) 0.10 (0.08-0.13) 
Selected pre-defined risk factors for HK    
Diabetes 1,360 (27.6%) 955 (20.4%) 1.35 (1.26-1.45) 
Chronic kidney disease ‡ 3,209 (65.0%) 2,023 (43.2%) 1.50 (1.45-1.56) 
Hypertension 4,201 (85.1%) 3,738 (79.9%) 1.07 (1.05-1.09) 
Other comorbidities    
Peripheral vascular disease 795 (16.1%) 577 (12.3%) 1.31 (1.2-1.44) 
Cerebrovascular disease 932 (18.9%) 744 (15.9%) 1.19 (1.1-1.30) 
Chronic pulmonary disease 1,116 (22.6%) 949 (20.3%) 1.11 (1.0-1.20) 
Peptic ulcer disease 511 (10.4%) 437 (9.3%) 1.11 (1.0-1.25) 
Any malignant disease 818 (16.6%) 651 (13.9%) 1.19 (1.08-1.31) 
Alcoholism-related disorders 458 (9.3%) 325 (6.9%) 1.34 (1.17-1.53) 
Medical obesity 435 (8.8%) 344 (7.4%) 1.20 (1.05-1.37) 
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Heart failure 
patients with 
first HK >5.0 
mmol/L 
Matched* 
heart failure 
comparisons 
without HK 
Matched 
Prevalence 
Ratio 
(95% CI) 
Use of hyperkalemia-associated medications    
ACEis overall 2,471 (50.1%) 2,186 (46.7%) 1.07 (1.03-1.12) 
Ramipril 1,231 (24.9%) 1,039 (22.2%) 1.12 (1.05-1.21) 
Enalapril 524 (10.6%) 426 (9.1%) 1.17 (1.03-1.32) 
Other ACEis 728 (14.8%) 722 (15.4%) 0.96 (0.87-1.05) 
ACEis/diuretics combination 120 (2.4%) 106 (2.3%) 1.07 (0.83-1.39) 
ARBs overall 734 (14.9%) 663 (14.2%) 1.05 (0.95-1.16) 
Losartan 335 (6.8%) 331 (7.1%) 0.96 (0.83-1.11) 
Candesartan 191 (3.9%) 119 (2.5%) 1.52 (1.21-1.91) 
Other ARBs 119 (2.4%) 107 (2.3%) 1.05 (0.81-1.36) 
ARBs/diuretics combination 146 (3.0%) 161 (3.4%) 0.86 (0.69-1.07) 
Spironolactone 1,908 (38.7%) 1,247 (26.7%) 1.45 (1.37-1.54) 
Potassium supplements 2,567 (52.0%) 2,539 (54.3%) 0.96 (0.92-1.00) 
Loop diuretics 3,438 (69.7%) 3,246 (69.4%) 1.00 (0.98-1.03) 
NSAIDs 1,039 (21.1%) 996 (21.3%) 0.99 (0.92-1.07) 
Trimetoprim 153 (3.1%) 156 (3.3%) 0.93 (0.75-1.16) 
Macrolides 607 (12.3%) 579 (12.4%) 0.99 (0.89-1.11) 
 
* Heart failure comparison patients without hyperkalemia matched on age, sex, and duration of heart failure on the 
hyperkalemia/index date 
 As present at the time of heart failure diagnosis.  
‡ Manifest chronic kidney disease was defined on the date of the second of two measurements more than 90 days apart 
of a creatinine value corresponding to an eGFR below 60 mL/min/1.73m2, or on the first date of a hospital diagnosis of 
chronic kidney disease, see text and Supplementary material with codes 
Abbreviations: ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-receptor II blockers; CI, 
confidence interval; eGFR, estimated Glomerular Filtration Rate; HK, hyperkalemia; NSAIDs, non-steroidal anti-
inflammatory drugs;PR, prevalence ratio 
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Table S13. Primary heart failure diagnosis: Hazard ratios for clinical outcomes 6 months 
after hyperkalemia (HK) versus fully matched comparisons without HK 
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  3,029 (2,949.79) 2,449 (1,680.51) 1.56 (1.47-1.66) 1.36 (1.27-1.46) 
Any acute hospitalization  3,465 (3,883.09) 1,872 (1,173.22) 2.66 (2.49-2.83) 2.16 (2.04-2.31) 
Any non-acute hospitalization  1,130 (767.97) 716 (364.29) 2.08 (1.87-2.30) 1.68 (1.50-1.93) 
Any cardiac diagnosis 2,874 (2,701.82) 1,546 (920.94) 2.43 (2.27-2.60) 2.15 (2.01-2.30) 
Ventricular arrhythmia 165 (93.24) 67 (31.10) 3.01 (2.21-4.12) 1.85 (1.32-2.79) 
Cardiac arrest 54 (29.75) 8 (3.69) 8.47 (3.91-18.33) 11.87 (3.12-70.70) 
Dialysis procedure 107 (59.68) 20 (9.23) 2.36 (1.43-3.89) 1.72 (1.07-2.68) 
Ventilator treatment 287 (162.76) 54 (25.01) 6.08 (4.48-8.24) 4.08 (2.39-7.15) 
ICU admission 565 (336.49) 140 (65.48) 5.24 (4.30-6.39) 4.13 (3.02-5.56) 
Heart failure re-admission 2,063 (1,606.34) 1,192 (671.69) 2.07 (1.91-2.24) 1.94 (1.81-2.10) 
ACEi prescription  2,021 (1,874.45) 2,130 (1,585.87) 1.05 (0.98-1.12) 0.98 (0.93-1.03) 
ARB prescription 525 (321.02) 607 (311.84) 0.95 (0.83-1.07) 0.98 (0.90-1.07) 
Spironolactone prescription 1,508 (1,148.79) 1,369 (806.60) 1.03 (0.95-1.12) 0.82 (0.78-0.88) 
Potassium supplement prescription  1,630 (1,271.59) 2,381 (1,833.14) 0.77 (0.72-0.82) 0.74 (0.69-0.78) 
Death 1,645 (903.28) 549 (252.85) 3.36 (3.02-3.74) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor II blocker, CI, confidence interval; HK, 
hyperkalemia; ICU, intensive care unit 
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Table S14. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully 
matched comparisons without HK, restricted to potassium measured in-hospital.  
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  5,087 (4,451.14) 4,206 (1,864.31) 1.96 (1.87-2.05) 1.55 (1.47-1.63) 
Any acute hospitalization  7,366 (18,262.56) 3,838 (1,726.00) 4.35 (4.16-4.55) 3.81 (3.63-4.02) 
Any non-acute hospitalization  2,092 (1,218.32) 1,368 (450.87) 2.35 (2.19-2.54) 1.93 (1.75-2.12) 
Any cardiac diagnosis 6,273 (8,756.88) 3,342 (1,417.80) 3.27 (3.12-3.42) 3.20 (3.03-3.39) 
Ventricular arrhythmia 389 (172.72) 184 (54.12) 2.69 (2.23-3.25) 2.91 (2.19-3.75) 
Cardiac arrest 146 (62.14) 34 (9.87) 6.21 (4.17-9.25) 10.04 (4.81-25.59) 
Dialysis procedure 147 (63.03) 48 (13.94) 2.25 (1.60-3.18) 1.74 (1.14-2.52) 
Ventilator treatment 951 (436.06) 150 (43.91) 8.48 (7.08-10.14) 5.35 (3.84-7.30) 
ICU admission 1,716 (875.82) 364 (108.40) 6.71 (5.96-7.56) 5.56 (4.63-6.95) 
Heart failure re-admission 4,708 (4,031.60) 2,716 (1,080.47) 2.45 (2.33-2.58) 2.66 (2.51-2.83) 
ACEi prescription  2,227 (1,398.51) 2,999 (1,312.24) 0.99 (0.93-1.05) 1.01 (0.96-1.07) 
ARB prescription 570 (260.35) 898 (286.35) 0.82 (0.73-0.91) 0.97 (0.89-1.04) 
Spironolactone prescription 1,597 (857.69) 1,852 (659.39) 1.06 (0.98-1.13) 0.88 (0.82-0.94) 
Potassium supplement prescription  2,467 (1,539.61) 3,749 (1,796.90) 0.84 (0.80-0.89) 0.77 (0.73-0.81) 
Death 3,727 (1,570.93) 1,152 (333.49) 3.92 (3.65-4.21) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor II blocker, CI, confidence interval; HK, 
hyperkalemia; ICU, intensive care unit 
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Table S15. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully 
matched comparisons without HK, restricted to potassium measured in the primary health 
care sector.  
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  2,673 (2,090.32) 2,238 (1,495.87) 1.26 (1.19-1.34) 1.26 (1.18-1.35) 
Any acute hospitalization  1,734 (1,070.90) 1,263 (693.57) 1.39 (1.28-1.50) 1.25 (1.16-1.35) 
Any non-acute hospitalization  694 (372.72) 545 (275.03) 1.29 (1.15-1.46) 1.26 (1.09-1.43) 
Any cardiac diagnosis 1,219 (689.96) 856 (444.82) 1.33 (1.20-1.46) 1.26 (1.15-1.40) 
Ventricular arrhythmia 61 (29.90) 46 (21.70) 1.03 (0.68-1.56) 1.29 (0.87-2.07) 
Cardiac arrest 10 (4.87) 7 (3.28) 1.72 (0.59-5.04) 2.05 (0.65-7.83) 
Dialysis procedure 76 (37.35) 13 (6.11) 1.65 (0.89-3.06) 0.72 (0.33-1.30) 
Ventilator treatment 39 (19.01) 35 (16.46) 1.07 (0.65-1.75) 0.98 (0.54-1.68) 
ICU admission 121 (59.49) 95 (45.00) 1.12 (0.83-1.50) 1.32 (0.93-1.88) 
Heart failure re-admission 601 (312.81) 431 (212.04) 1.26 (1.10-1.44) 1.20 (1.05-1.37) 
ACEi prescription  2,203 (1,799.25) 1,864 (1,311.05) 1.09 (1.02-1.17) 0.93 (0.89-0.96) 
ARB prescription 653 (358.75) 508 (260.31) 1.27 (1.12-1.45) 1.04 (0.97-1.12) 
Spironolactone prescription 1,585 (1,048.59) 1,024 (573.22) 1.04 (0.96-1.14) 0.81 (0.76-0.85) 
Potassium supplement prescription  1,642 (1,098.47) 2,170 (1,586.37) 0.76 (0.71-0.81) 0.73 (0.70-0.77) 
Death 730 (355.17) 390 (182.92) 2.00 (1.74-2.30) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor II blocker, CI, confidence interval; HK, 
hyperkalemia; ICU, intensive care unit 
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Table S16. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully 
matched comparisons without HK, restricted to patients with less than 10 potassium tests.  
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  4,278 (3,053.33) 3,954 (2,014.09) 1.39 (1.33-1.46) 1.36 (1.29-1.44) 
Any acute hospitalization  5,359 (4,953.68) 3,752 (1,994.11) 1.96 (1.88-2.05) 2.07 (1.97-2.17) 
Any non-acute hospitalization  1,564 (770.64) 1,391 (521.71) 1.41 (1.30-1.52) 1.61 (1.45-1.79) 
Any cardiac diagnosis 4,660 (3,597.83) 3,326 (1,665.22) 1.78 (1.70-1.86) 1.94 (1.83-2.06) 
Ventricular arrhythmia 266 (109.04) 181 (59.60) 1.73 (1.41-2.11) 2.30 (1.72-3.10) 
Cardiac arrest 102 (40.73) 32 (10.37) 4.11 (2.71-6.24) 8.30 (3.48-25.71) 
Dialysis procedure 105 (42.15) 48 (15.56) 1.41 (0.98-2.02) 0.97 (0.63-1.40) 
Ventilator treatment 577 (241.00) 146 (47.76) 4.76 (3.94-5.74) 5.04 (3.71-7.59) 
ICU admission 1,009 (444.64) 371 (123.88) 3.41 (3.01-3.86) 4.17 (3.40-5.17) 
Heart failure re-admission 3,790 (2,445.76) 2,769 (1,292.29) 1.61 (1.53-1.70) 1.78 (1.68-1.88) 
ACEi prescription  2,514 (1,576.24) 2,700 (1,318.74) 1.04 (0.98-1.10) 0.95 (0.91-1.00) 
ARB prescription 680 (297.26) 750 (264.99) 1.05 (0.95-1.17) 1.06 (0.97-1.14) 
Spironolactone prescription 1,738 (897.09) 1,701 (679.34) 1.04 (0.97-1.12) 0.81 (0.76-0.86) 
Potassium supplement prescription  2,112 (1,157.71) 3,462 (1,877.08) 0.69 (0.66-0.74) 0.70 (0.66-0.74) 
Death 2,568 (1,018.82) 1,172 (378.73) 2.65 (2.46-2.85) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor II blocker, CI, confidence interval; HK, 
hyperkalemia; ICU, intensive care unit 
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Table S17. Hazard ratios for clinical outcomes 6 months after hyperkalemia (HK) versus fully 
matched comparisons without HK, restricted to patients with 10 or more potassium tests.  
 
Heart failure 
patients with first 
HK >5.0 mmol/L 
Matched* heart 
failure comparisons 
without HK   
Outcome 
n (Rate per 1,000 
person-y) 
n (Rate per 1,000 
person-y) 
Fully adjusted† 
Hazard Ratio 
(95% CI)  
Prior-event-rate-
ratio adjusted‡ 
Hazard Ratio 
(95% CI) 
Any hospital outpatient contact  3,482 (3,412.02) 2,490 (1,391.83) 1.98 (1.87-2.10) 1.46 (1.37-1.57) 
Any acute hospitalization  3,741 (3,976.74) 1,349 (623.64) 4.59 (4.28-4.93) 2.93 (2.74-3.15) 
Any non-acute hospitalization  1,222 (788.58) 522 (222.18) 3.30 (2.94-3.70) 1.97 (1.75-2.23) 
Any cardiac diagnosis 2,832 (2,384.05) 872 (381.75) 4.53 (4.15-4.94) 3.40 (3.11-3.72) 
Ventricular arrhythmia 184 (99.32) 49 (19.74) 3.96 (2.79-5.62) 3.14 (2.17-4.57) 
Cardiac arrest 54 (28.41) 9 (3.61) 9.28 (3.88-22.16) 8.59 (3.14-34.09) 
Dialysis procedure 118 (62.91) 13 (5.22) 3.05 (1.69-5.50) 1.84 (1.01-3.21) 
Ventilator treatment 413 (224.65) 39 (15.69) 15.04 (10.40-
21.74) 
5.44 (3.43-9.06) 
ICU admission 828 (480.27) 88 (35.57) 11.64 (9.21-14.71) 7.16 (5.39-9.62) 
Heart failure re-admission 1,519 (986.73) 378 (157.26) 4.72 (4.15-5.38) 4.08 (3.61-4.65) 
ACEi prescription  1,916 (1,568.09) 2,163 (1,303.21) 1.00 (0.93-1.07) 1.03 (0.99-1.08) 
ARB prescription 543 (315.34) 656 (290.62) 0.93 (0.81-1.06) 1.00 (0.93-1.08) 
Spironolactone prescription 1,444 (1,005.45) 1,175 (561.90) 1.04 (0.95-1.13) 0.92 (0.87-0.98) 
Potassium supplement prescription  1,997 (1,568.89) 2,457 (1,526.17) 0.94 (0.88-1.01) 0.83 (0.79-0.87) 
Death 1,889 (990.44) 370 (148.48) 5.60 (4.94-6.36) - 
 
* Heart failure comparisons without HK individually matched to heart failure patients with HK on age, sex, and heart failure duration, 
see text. 
 
†Adjusted for age, sex, and heart failure duration by matched design, and, by Cox regression analyses, for heart failure treatment 
regimen, number of acute heart failure hospitalizations 6 months before the HK/index date, eGFR category, Charlson Comorbidity 
Index score, presence of diabetes/chronic kidney disease/ hypertension, use of ACEis/ARBs, spironolactone, or potassium 
supplements 
 
‡The prior-event-rate-ratio adjusted hazard ratio is the ratio of the two age, sex, and heart failure duration matched rate ratios 
observed 6 months after vs. 6 months before the HK/index date, see text 
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor II blocker, CI, confidence interval; HK, 
hyperkalemia; ICU, intensive care unit 
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Figure S1. Required strength of an unmeasured confounder to explain our associations 
assuming that 50% of the heart failure population had hyperkalemia and that the prevalence 
of the unmeasured confounder was 25%.  
 
*HR indicates hazard ratio for the association between hyperkalemia and the different outcomes. 
For example, to explain an adjusted HR of ~ 2.0 (brown line) for acute hospitalization associated 
with hyperkalemia, a confounder that is four times more frequent among hyperkalemia than non-
hyperkalemia patients would need to increase the hazard of acute hospitalization by a factor of 10 or 
more to explain our findings fully, if no increased hazard actually existed.  
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